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ABSTRACT OF DISSERTATION

NOVEL ROLE OF CD47 IN OBESITY-ASSOCIATED METABOLIC
DYSFUNCTIONS
Obesity and its associated comorbidities are of global concern. These
complications are largely driven by perturbations in energy homeostasis,
inflammation, and oxidative stress within metabolic tissues. Although these
underlying pathways have been established, molecular mechanisms augmenting
metabolic dysfunction have not been fully defined. CD47, a ubiquitously
expressed cell membrane receptor, has been previously implicated in the
development of inflammation and oxidative stress in a number of disease
conditions. Previous work from our lab and others has confirmed that the most
potent ligand of CD47, TSP1, plays a critical role in facilitating inflammation and
metabolic dysfunction in diet-induced obesity. Whether these effects of TSP1 are
mediated by CD47 has never been explored. Specifically, the functions of CD47
in white and brown adipose tissue, skeletal muscle, and the liver have never
been characterized under obese conditions. Within our studies, we clearly
defined distinct regulatory functions of CD47 in different metabolic tissues of a
diet-induced obesity rodent model. We found that CD47 deficiency was
associated with reduced adiposity and systemic inflammatory markers which
preserved glucose homeostasis. In white adipose tissue, CD47 deficiency was
associated with suppressed inflammation and macrophage recruitment which
may be attributed to smaller adipocyte size driven by enhanced lipid mobilization.
Further, whole body CD47 deficiency stimulated brown adipose tissue energy
expenditure through increased FFA-mediated uncoupling and enhanced fatty
acid oxidation. Interestingly, no significant changes were observed in skeletal
muscle-dependent energy expenditure. In the liver, both TSP1 and CD47
deficiency protected mice from diet-induced fatty liver disease. In vitro studies
demonstrated that TSP1 induces liver oxidative stress comparable to free fatty
acids and that CD47 blockade partially attenuates this effect. From these studies,
we concluded that increased lipid turnover fueled the enhanced energy
requirements of activated brown adipose tissue resulting in a leaner phenotype
despite high fat diet challenge. In addition, the increased TSP1-CD47 protein
expression in the liver may augment ROS in fatty liver disease. Together, these
studies provide evidence to suggest CD47 may contribute to metabolic

dysfunction in a tissue-specific manner and that the pathological roles of CD47
function should expand to include obesity and its associated comorbidities.
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Section 1: BACKGROUND
1.1 Defining Obesity
Over the past thirty years, obesity has become a global health concern.
Obesity, or an excessive accumulation of fat (lipid), is a result of significant
expansion of adipose tissue depots and the deposition of lipid in other organs.
The greatest cause of obesity is increased energy consumption paired with a
lack of energy expenditure. As a consequence, serious systemic metabolic
dysfunctions occur due to increased lipid deposition. Many obesity-associated
comorbidities are a result of impaired adaptive mechanisms to manage increased
lipid burden.
Evolutionarily, our bodies have become increasingly efficient at storing
excess energy for times of need. Initially, humans could go long periods of time
fasting as they hunted and searched for food; relying on the hydrolysis of
triglycerides (TGs) in adipose tissue stores to release free fatty acids (FFAs),
glycogenolysis (break down of glycogen), gluconeogenesis (conversion of noncarbohydrate sources to glucose), and ketogenesis (production of ketone bodies)
for energy. As our food availability has rapidly progressed in comparison to the
evolution of biological mechanisms, overweight and obesity have become
common concerns due to the redundant mechanisms in place that lead to energy
storage.
1.1.1 Prevalence of Obesity
The obesity epidemic is not restricted to a specific population or region of
the world. In 2014, the World Health Organization reported that approximately
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39% of the global adult population was overweight and 13% were considered
obese (290). It is predicted by 2030 that roughly 57% of the global adult
population will be either overweight or obese (123). Although obesity is a global
issue, certain populations are at a disproportionate risk of developing obesity and
its associated complications. Around the world, developing countries adopting
elements of western culture, such as increased processed food consumption and
sedentary behaviors, are experiencing dramatic increases in obesity rates. For
example, it is predicted that over 60% of the world’s obese adult population
reside in developing or developed nations (182). Within the United States, the
rates of obesity in Hispanic and African American populations are 42.5% and
47.8%, respectively (190). What is most concerning about the staggering rates of
obesity is that significant adiposity typically serves as a predictor for a number of
serious metabolic dysfunctions including type 2 diabetes, cardiovascular disease,
and even some cancers.
The most common measurement used to determine obesity prevalence is
body mass index (BMI; weight in kilograms divided by height in meters squared).
In adults, a BMI of 30 or greater is considered obese. Another simple and reliable
method is waist circumference. Men and women with waist circumferences
greater than 40 inches (102cm) and 35 inches (88cm), respectively, are
considered obese and at increased risk for obesity-associated complications
(111). Some suggest waist circumference or waist-to-hip ratios are more
accurate metrics for obesity because BMI is unable to distinguish weight as fat or
lean mass.
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1.1.2 Characteristics of Adipose Tissue
Adipocytes (fat cells) are the primary lipid storage cell within the body.
Although they are responsible for 95% of the volume of adipose tissue depots,
this cell type only constitutes 25% of the cell population in adipose tissue (140).
Other cell types include endothelial cells, pericytes, pre-adipocytes, and immune
cells. As FFAs enter the adipocyte, the enzyme acyl CoA synthase (ACS)
attaches coenzyme-A (CoA) thioesters to FFAs forming fatty acyl-CoA. Through
an esterification process, three fatty acyl-CoA residues are esterified to a glycerol
backbone forming triglyceride (TG; triacylglycerol) (48). Due to its hydrophobic
nature, the endoplasmic reticulum (ER) packages lipid (TG and cholesterol
esters) within the cell into lipid droplets coated with phospholipids and lipiddroplet associated proteins (159). Several extracellular signals can activate
hydrolysis of TG within lipid droplets to provide FFAs as an energy substrate for
ATP production in times of energy deprivation. Lipolysis is mediated by several
lipases including adipose triglyceride lipase (ATGL), hormone sensitive lipase
(HSL), and monoglyceride lipase (MGL) (301).
Recent studies have determined that WAT depots are not just inert energy
storage depots, but rather dynamic tissues with endocrine and paracrine
functions. In addition to their plasticity, adipose tissue can receive both hormonal
and afferent neuronal signals suggesting dynamic interactions and crosstalk with
other tissues (223). Adipose tissue can respond by secreting molecules involved
in regulating a number of pathways including hunger, energy metabolism, and
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inflammatory responses. These molecules include growth factors, cytokines,
chemokines, acute phase proteins, and adipokines.
During obesity-associated adipose tissue expansion, two primary
processes contribute to tissue growth and remodeling. Adipocytes accommodate
more lipid by enlarging the storage capacity within a single cell resulting in
adipocyte hypertrophy (single cell expansion) (45). Second, resident stem celllike preadipocytes begin to terminally differentiate resulting in new adipocytes to
sequester increased lipid burden within the adipose tissue depot. This expansion
in cell number is called hyperplasia (140). Specific adipogenic transcription
factors, such as peroxisome proliferator-activated receptor-γ (PPARγ) and
members of the CCAAT/enhancer-binding protein (C/EBP) family, largely
mediate the differentiation of new adipocytes (222). As a result, adipocytes are
now considered one of the most morphologically dynamic cell types capable of
adjusting cell size and number to accommodate increased energy substrate
storage.
Lineage tracing studies suggest that the formation of different adipose
tissue depots is determined at the level of the stem cell progenitor. Although all
adipocyte differentiation mechanisms are largely mediated by PPARγ and C/EBP
family members (222), white adipocytes are derived from different progenitor
cells than other types of adipocytes. For example, white adipocytes rise from
Myf5-negative progenitors while brown adipocytes more closely resemble
skeletal muscle in the Myf5-positive lineage (234).
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1.1.2.1 White Adipose Tissue (WAT)
Over the past decade it has been determined that mammals, including
humans, have various types of adipose tissue responsible for different functions.
As previously described, white adipose tissue (WAT) is primarily responsible for
storing lipid until times of need and sequestering excess lipid to prevent
lipotoxicity in other tissues. WAT is characterized by adipocytes with large
singular lipid droplets (unilocular), low basal energy expenditure, and very little
protein/mitochondrial content which contributes to its white morphology.
WAT plays a unique role in regulating food intake, energy expenditure,
and metabolic function in other tissues through the production and secretion of
several adipokines (secreted from adipocytes). For example, leptin was identified
in 1994 as an adipokine in which plasma levels positively correlate to adipose
tissue mass (305). Mice lacking the leptin gene are hyperphagic and morbidly
obese; however chronic leptin administration drastically reduces body weight,
suppresses hunger, and induces fatty acid oxidation (91, 201). Leptin elicits
these effects by signaling to the arcuate nucleus, the hunger center of the brain,
to suppress food intake and stimulate physical activity. Although leptin seemed
like a promising anti-obesity therapeutic in the 1990s and early 2000s, it was
soon discovered that obese individuals exhibit hyperleptinemia and develop a
form of leptin resistance, which abolishes all anorexigenic effects of the protein
on the brain (161, 262).
Another well-characterized adipokine is adiponectin. Unlike leptin, plasma
adiponectin levels negatively correlate with BMI and adipose tissue mass. The
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primary function of adiponectin is to improve insulin sensitivity, increase skeletal
muscle and adipose tissue glucose uptake, and suppress hepatic glucose
production (82, 161). In addition to adipokines, cytokines and chemokines may
be secreted from resident adipose tissue macrophages (ATMs) that stimulate
various effects on other peripheral tissues.
1.1.2.2 Brown Adipose Tissue (BAT)
In addition to WAT depots, brown adipose tissue (BAT) is another type of
adipose tissue that has been recently identified in adult humans. BAT was
thought to only exist in human infants and other small mammalian species with
large surface to volume ratios – reason being the need for mechanisms to
regulate whole body temperature homeostasis. However, in 2009, four
independent

studies

confirmed

with

positron-emission

tomography

with

computed tomography (PET-CT) scans the presence of an adipose tissue depot
in humans located in the paracervical and supraclavicular region with enhanced
glucose uptake and robust metabolic activity (54, 226, 267, 273).
Once activated, BAT catabolizes lipid and other energy substrates at an
accelerated

rate

to

maintain

non-shivering

thermogenesis

(shivering

thermogenesis is a result of skeletal muscle heat generation). This specific
mechanism unique to BAT is largely dependent on the mitochondrial protein,
uncoupling protein 1 (UCP1) (184), which is associated with the inner
mitochondrial membrane, is activated by FFAs, and dissipates chemical energy
as heat by uncoupling the electron transport chain (ETC) (30). As a result, BAT
morphology is different from WAT in that it has high protein content due to
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increased mitochondrial density, multiple lipid droplets per cell (multilocular) to
increase surface area and fuel accessibility, and enhanced blood flow for lipid
oxidation (94).
The most potent activator of BAT-driven energy expenditure is the
sympathetic nervous system in response to cold exposure. This mechanism is
mediated by the release of norepinephrine and activation of β-adrenergic
receptors on the brown adipocyte cell surface. Other physiological activators of
BAT

activity include fibroblast

growth

factors, thyroid

hormone,

bone

morphogenetic proteins, certain myokines (e.g. irisin), and abundant FFAs (26,
67, 71, 142, 204, 284). Certain compounds have been identified that activate
UCP1-driven energy expenditure in humans including common nutraceuticals
(e.g. capsinoids, capsaicin) and β-adrenergic receptor agonists (55, 227). In
efforts to pharmacologically stimulate BAT through β-adrenergic stimulation,
several studies have been deemed unsuccessful due to off-target effects on the
cardiovascular system.
Although

studies

are

inconclusive

on whether

BAT

in

humans

phenocopies classical interscapular BAT of rodents, it is clear that activated BAT
in humans and rodents can regulate whole body lipid homeostasis. In 2011,
Bartelt et al. clearly demonstrated that BAT, despite low tissue mass/body weight
ratios, can uptake approximately 50% of dietary TGs in rodents (17). They even
showed cold-induced BAT activation could protect hyperlipidemic genetic rodent
models from deleterious cardiovascular events (17). FFAs are an ideal energy
source because they provide abundant energy to sustain constant UCP1-
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dependent uncoupling within activated BAT. Studies in humans have shown that
only 50g (~0.1lbs) of BAT could contribute to ≤20% basal caloric requirements
(224). Over the past few years, exploiting the potential of BAT energy
expenditure

has become

a

popular target

for developing anti-obesity

therapeutics.
1.1.2.3 Beige Adipose Tissue
Beige adipose tissue is primarily located within WAT depots; however, it
shares several similar characteristics with BAT. These adipocytes are still
capable of storing large amounts of lipid, yet respond to cold exposure and βadrenergic stimulation to drive UCP1-dependent energy expenditure (291).
Interestingly, these adipocytes are from the same Myf5 negative lineage as white
adipocytes and express unique beige adipocyte markers (Cd137, Tmem26) (234,
291), suggesting they are a distinct cell type not related to brown adipocytes.
Further, there are several anatomically-distinct WAT depots in rodents and
humans, but beige adipocytes have only been identified in retroperitoneal and
subcutaneous depots (223). Some suggest future anti-obesity studies should
target beige adipose tissue or the “browning” of white adipose tissue rather than
BAT due to the substantial differences in WAT and BAT mass in humans. A
comparison of the three distinct forms of adipose tissue can be found in Table
1.1.
1.2 Pathophysiology of Obesity
When examining the pathophysiology of obesity, it is important to
understand how body fat distribution in obesity contributes to metabolic
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dysfunction. It has been established that visceral or central obesity located in the
abdominal trunk is more pathological than other depots such as subcutaneous
adipose tissue. It has been well established through numerous longitudinal
studies that central adiposity alone is an independent predictor of insulin
resistance and cardiovascular disease (35, 134, 192). Visceral adipose tissue
has direct access to portal vein circulation; therefore, dysregulated lipolysis leads
to increased flux of FFA into circulation reaping deleterious effects on hepatic
function and cardiovascular health (20, 23).
It is clear that the development of obesity is multifactorial and negatively
impacts a number of tissues and organ systems. As a result of adipose tissue
expansion through hypertrophy, the secretion of adipokines and inflammatory
molecules become dysregulated. For example, expression of adiponectin, the
anti-inflammatory and insulin-sensitizing hormone, is significantly reduced in
adipose tissue and in circulation of obese individuals (161).
1.2.1 Obesity-associated Inflammation
It is now widely accepted that obesity is a condition characterized by lowgrade chronic inflammation. Adipose tissue remodeling and expansion in
response to high fat diet stimulates resident ATMs to secrete several
proinflammatory cytokines and chemokines (see Figure 1.1) (141, 281). In 1993,
Hotamisligl et al. determined circulating levels and adipose tissue expression of
tumor necrosis factor-α (TNFα) were significantly upregulated in obese rodent
models (96). Several subsequent studies confirmed a direct role of TNFα in
mediating insulin resistance by impairing glucose disposal in liver, muscle, and
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adipose tissues (225, 248, 265). It has even been shown that TNFα deficiency in
a diet-induced obese rodent model improved peripheral insulin sensitivity
compared to controls (265), suggesting a systemic role of TNFα in obesityassociated insulin resistance. Further, it has been determined that ATMs are
primarily responsible for recruiting additional immune cells to adipose tissue
depots by way of chemokines such as monocyte chemoattractant protein 1
(MCP1) (117). Other cytokines and chemokines implicated in the pathogenesis of
obesity-associated

inflammation

include

interleukin-6

(IL-6),

plasminogen

activator inhibitor-1 (PAI-1), and IL-1β (70, 196). Together, these mechanisms
augment systemic and adipose tissue-specific proinflammatory environments,
which promote other obesity-associated complications.
1.2.2 Dyslipidemia
Another characteristic of obesity is the presence of dyslipidemia, or
pathological levels of lipid in circulation. Increased circulating FFAs are a result of
rampant lipid turnover in adipose tissue. As a result, metabolic tissues such as
muscle and liver will utilize FFAs as a preferred energy substrate for ATP
production and reduce glucose disposal from circulation (208). In addition,
hepatic uptake of plasma FFAs will induce gluconeogenesis further exacerbating
hyperglycemic conditions (285). Hypertriglyceridemia and elevated plasma FFA
levels will also affect lipoprotein metabolism by increasing very-low density
lipoprotein (VLDL) and low-density lipoprotein (LDL) production and suppressing
the assembly of protective high density lipoprotein (HDL) particles. To further
exacerbate the issue, chronically elevated plasma FFAs commonly observed

10

under obese conditions impair insulin secretion from the pancreas in response to
hyperglycemia blunting glucose disposal by insulin-sensitive tissues (307).
1.2.3 Insulin Resistance
Insulin resistance is another contributor to the pathophysiology of obesity.
Insulin, a hormone secreted from beta cells within the pancreas, stimulates
glucose uptake and energy storage in muscle, adipose tissue, and the liver in
order to maintain tight regulation of blood glucose levels. Several mechanisms
work tightly to control blood glucose concentrations at physiological levels in
times of fasting (92); however, hepatic insulin resistance perpetuates
hyperglycemia even in fed conditions. Once the liver no longer responds to
insulin, it is unable to suppress glucose production via gluconeogenesis and
glycogenolysis. In addition, insulin resistance in the liver drives deregulated de
novo lipogenesis and lipid trafficking to peripheral tissues. Adipose tissue is
another insulin-responsive tissue. In addition to glucose uptake in adipose tissue,
a critical function of insulin is to inhibit hydrolysis of TGs and promote lipid
storage. However, in insulin resistant adipose tissue, insulin is unable to blunt
lipolysis which leads to an increased flux of FFAs out of adipose tissue into
circulation which further propagates dyslipidemic conditions in obesity. This
vicious cycle triggers the continued secretion of insulin from the pancreas,
ultimately resulting in the development of overt type 2 diabetes mellitus (282),
highlighted in more detail in Section 1.2.1.1.
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1.2.4 Obesity-associated Brown Adipose Tissue Dysfunction
Knowing adult humans have functional BAT depots, which require
increased energy substrates, recent studies have targeted BAT function as an
anti-obesity therapeutic strategy to help restore global energy balance. In one
study examining differences in BAT activity between lean and overweight/obese
adult men, it was determined that BAT activity negatively correlates with BMI and
body fat percentage (267). It has also been shown in humans that obesity
significantly blunts cold-induced BAT activation and glucose uptake compared
with lean controls (197). In addition, rodent models have begun to elucidate the
effects of obesity on BAT morphology and function. Although lean and obese
rodents have similar BAT mass (156), BAT function is impaired as demonstrated
by reduced blood flow and insulin resistance in rodents, as well as suppressed
metabolic activity in rodents and humans (197, 215, 237). Several genes
implicated in BAT-mediated energy expenditure, including UCP1, are significantly
downregulated with HF diet, which augments impaired BAT function in obese
rodent models (237). Identifying mechanisms that preserve BAT function under
obese conditions could provide novel anti-obesity therapeutic targets.
1.2.5 Obesity-associated Comorbities
It is clearly evident that the pathology of obesity is not restricted to adipose
tissue, but causes deleterious effects on several organ systems and their
functions. This is illustrated in Figure 1.2. Obesity increases the risk of
developing a number of complications including type 2 diabetes mellitus (T2DM),
cardiovascular disease (CVD), non-alcoholic fatty liver disease (NAFLD), stroke,

12

sleep apnea, certain cancers, gallbladder disease, and gout (21, 72, 203).
Further, men and women classified as obese according to BMI are at even
greater risk for all-cause mortality (283).
1.2.5.1 Type II Diabetes Mellitus (T2DM)
T2DM is a metabolic condition characterized by hyperglycemia and
impaired responses to insulin signaling and reduced glucose disposal. In the
United States, it is estimated that approximately 15% of individuals are living with
T2DM, whether diagnosed or undiagnosed (50). As previously mentioned, insulin
resistance perpetuates a vicious cycle that exacerbates hyperglycemic
conditions, causing the pancreas to continuously secrete insulin in response to
elevated plasma glucose. Ultimately, the pancreas is unable to compensate for
hyperglycemia resulting in impaired insulin release. The presence of T2DM has
also been shown to be a strong risk factor for micro- and macrovascular
complications including nephropathy, retinopathy, neuropathy, dementia, and
cardiovascular disease.
1.2.5.2 Cardiovascular Disease (CVD)
Cardiovascular disease (CVD) is a collective term for dysfunctions
associated with the heart and vasculature, which includes coronary heart
disease, cerebrovascular disease, and atherosclerosis. Collectively, CVD is the
number one cause of mortality worldwide (168). A 26-year follow up of the
Framingham Heart Study established that obesity alone was an independent risk
factor for the development of CVD in both men and women (99). In combination,
obesity and insulin resistance associated with T2DM drastically increase the risk
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of an individual developing CVD. To demonstrate the tight association between
T2DM and CVD, several studies suggest T2DM is a significant independent risk
factor for CVD (287, 288) and it has been determined that the cause of mortality
in over two thirds of all individuals diagnosed with T2DM is CVD (86).
1.2.5.3 Non-Alcoholic Fatty Liver Disease (NAFLD)
Due to the dramatic rise in obesity and central adiposity, non-alcoholic
fatty liver disease (NAFLD) has become the most common liver disease around
the world. NAFLD is defined as lipid accumulation in ≥5% of hepatocytes not
attributed to alcohol consumption, medications, or other disease states (37).
Primarily, diet-induced obesity is the largest known cause for the development of
NAFLD. Moreover, NAFLD is considered a progressive disease that can range
from simple steatosis and fibrosis, to the development of non-alcoholic
steatohepatitis (NASH), cirrhosis, and ultimately hepatocellular carcinoma (HCC)
(2). Because of the critical role of the liver in whole body glucose and lipid
homeostasis, patients diagnosed with NAFLD are at an increased risk of
developing T2DM, CVD, and metabolic syndrome (3, 259).
1.2.5.4 Metabolic Syndrome
Metabolic syndrome is a condition in which an individual presents a
combination of pathological metabolic factors that significantly enhance the
likelihood of developing CVD and all-cause mortality. Although several definitions
for metabolic syndrome have been established by different health organizations
over the past several decades, a consensus was reached in 2009 by the
International Diabetes Federation, National Institutes of Health, American Heart
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Association, World Health Federation, International Atherosclerosis Society, and
International Association for the Study of Obesity. This publication stated that the
diagnosis of metabolic syndrome would include the presence of three out of five
specific components (5). These specific components include 1) increased waist
circumference, 2) hypertriglyceridemia (≥150mg/dL), 3) reduced HDL cholesterol
(<40mg/dL in males; <50mg/dL in females), 4) hypertension (systolic ≥ 130
mmHg

and/or

diastolic

≥85

mmHg),

5)

and/or

fasting

hyperglycemia

(≥100mg/dL).
1.3 NAFLD: Impacts on Metabolic Health
Like obesity, NAFLD has become a global health concern. Because the
prevalence of NAFLD is so tightly linked to obesity, incidence rates have
significantly increased over the past few decades. Although the prevalence rates
of NAFLD vary depending on diagnostic techniques and the population of
interest, it is estimated that one third of the United States adult population
present NAFLD (29). Moreover, 20-30% of the adult populations in Europe, the
Middle East, and Asia are also thought to have NAFLD (12, 66, 209).
Variability is high in estimating the prevalence of NAFLD around the world
due to differences in diagnostic criteria, access to medical technology, and
subjectivity to pathological analysis. Primarily, ultrasonography is the most
commonly used qualitative measure of hepatic lipid accumulation. Other imaging
techniques including computerized tomography (CT), magnetic resonance
spectroscopy (MRS) and magnetic resonance imaging (MRI) are also used (7);
however, accessibility and cost for more advanced imaging is restricted in some
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locations around the world. Alanine transaminase (ALT), a serum biochemical
marker upregulated in the presence of liver injury, has been used as an indicator
of NAFLD development for a number of years. It has even been shown that
elevated serum ALT levels in humans correspond with an increased risk of
developing end-stage liver disease (61). More recently, studies suggest
monitoring serum ALT levels could grossly underestimate the prevalence of
NAFLD because some patients with progressive fatty liver can present normal
serum ALT levels (269). Distinguishing cases of NAFLD from more advanced
forms of steatosis are very difficult with imaging techniques and serum
biomarkers. Liver biopsies are preferred for quantitatively determining the
severity of the steatosis yet is a much more involved diagnostic criteria and is still
subject to sampling bias and inaccurate interpretation (7).
1.3.1 Hepatic Lipid Metabolism
The liver is a dynamic organ responsible for a number of metabolic
processes. In particular, the liver plays an integral role in whole body lipid
metabolism and homeostasis. A number of mechanisms are involved in
regulating the amount of lipid within the hepatocyte, with the goal to maintain
very low levels of intracellular FFAs. These pathways include fatty acid uptake,
de novo lipogenesis/TG synthesis, fatty acid oxidation, and TG export to
peripheral tissues through lipoprotein secretion.
As FFAs arrive at the liver, they are taken up into hepatocytes by fatty acid
transport proteins (FATP2, FATP5), fatty acid translocases (FAT/CD36), or they
diffuse freely across the plasma membrane due to their lipophilic nature. It is
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unclear whether FFA uptake from circulation into the liver is regulated; however,
some suggest that the amount of FFA uptake is directly proportional to the FFA
concentration in circulation (121). Once in the cell, there are a number of fates for
FFAs. Immediately, FFAs are bound to fatty acid binding protein (FABP) or acylCoA by way of acyl-CoA synthases (ACS) and are transported to various
locations in the cell. Some FFAs function as signaling molecules and activate a
number of nuclear receptors and transcription factors implicated in lipid
metabolism including sterol regulatory element binding proteins (SREBPs) and
liver X receptors (LXRs) (124, 296).
As a highly energetic organ, the liver relies on FFAs as a constant and
efficient fuel supply for the production of adenosine triphosphate (ATP) within
mitochondria. In hepatic β-oxidation, entry into mitochondria for FFA species 14
carbons or longer is mediated by the enzyme carnitine palmitoyltransferase-1a
(CPT1a). This enzyme converts FFA to acyl-carnitine in order to be transported
across the mitochondrial membrane. FFA species 12 carbons or less are able to
pass through the mitochondrial membrane without a transport system (232).
CPT1a serves as the rate-limiting step of β-oxidation, acting as a switch so that
the synthesis of FFAs as well as the catabolism of FFAs does not occur
simultaneously. To a lesser extent, very long chain FFAs can be catabolized
within peroxisomes yielding much less ATP due to their lack of an electron
transport chain (ETC).
A critical function of the liver is to assemble lipids into VLDL particles and
export them out of the liver to other peripheral tissues either for energy or
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storage. The enzyme microsomal triglyceride transfer protein (MTTP) is required
for the packaging and secretion of VLDL from the liver. It has even been
demonstrated in rodents that genetic and pharmacological interruptions in MTTP
function significantly blunt VLDL secretion and result in increased hepatic lipid
accumulation (145). This indicates just how critical hepatic lipoprotein assembly
is for maintaining hepatic lipid homeostasis.
In excess, FFAs are esterified and stored in the form of TG within the
cytosol of the hepatocyte either for future use or as a mechanism to protect the
cell from FFA-induced cellular dysfunction. TG synthesis is largely regulated by
SREBP-1c, LXRs, carbohydrate regulatory element binding protein (ChREBP),
PPARγ, and the overall energy state within the cell (47, 58). If cellular fuel (ATP)
is low, acyl-CoA and FFAs are shunted into the β-oxidation pathway and TG
synthesis is repressed (175).
1.3.2 Pathophysiology of NAFLD
Elevated intrahepatic triglyceride associated with NAFLD contributes to an
imbalance in lipid, glucose, and lipoprotein metabolism. NAFLD is characterized
by increased lipid deposition in hepatocytes, a result of enhanced TG synthesis
as well as elevated oxidative stress and inflammation driven by FFA-induced
lipotoxicity. Together, these two factors are closely linked to insulin resistance;
however, it has not been fully determined whether NAFLD is the cause or simply
a result of insulin resistance. Some rodent studies suggest that high fat (HF) diet
challenge for acute periods of time (few days) can significantly impair insulin
signaling in the liver prior to systemic effects of diet-induced obesity, suggesting
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the liver plays a central role in the development of whole body insulin resistance
(228).
Oxidative stress and low-grade chronic inflammation are consistently
observed in NAFLD and cardiometabolic disorders (69, 221). In NAFLD, elevated
FFAs levels in portal circulation from both dietary consumption and increased
adipose tissue lipolysis are taken up by hepatocytes, which drive intracellular
oxidative stress (180). Oxidative stress is a result of impaired cellular capacity to
maintain a balance between detoxifying mechanisms and the production of
reactive oxidative species (ROS), molecules with unpaired electrons. Some of
the most commonly observed forms of ROS include superoxide anions (·O2-),
hydrogen peroxide (H2O2), and hydroxyl radicals (·OH).
In lipotoxic conditions, protective mechanisms triggered by the hepatocyte,
such as increased mitochondrial respiration and activated antioxidant pathways,
are compromised further exacerbating oxidative stress within the cell (115, 231).
Mitochondria will respond to increased lipid burden by activating the fatty acid
oxidation pathway as a compensatory mechanism to maintain low levels of FFA
within the cell. However, after chronic burden, the mitochondria begin to produce
ROS through enhanced electron leakage and subsequently contribute to the poor
oxidative environment within the cell (230, 243). In addition, nuclear factor E2related factor 2 (Nrf2), a critical transcription factor that regulates the expression
of several cytoprotective enzymes, is significantly downregulated by NAFLD
(243). These protective enzymes include glutathione S-transferase (GST)
enzymes, NADPH quinone oxidoreductase 1 (NQO1), and heme oxygenase 1
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(HO-1) (183). Reduced expression of these genes contributes to the imbalance
between detoxification and ROS production classically observed in the presence
of fatty liver. Several studies have focused on ways to activate and preserve Nrf2
signaling despite the progression of NAFLD as a potential mechanism to protect
against hepatic lipid accumulation and insulin resistance (60, 139, 205)
Many of the deleterious effects of oxidative stress are a consequence of
damaged intracellular lipids, proteins, and nuclear and mitochondrial DNA which
are highly susceptible in poor oxidative environments. In the case of fatty liver
disease where intracellular lipid is elevated, lipid peroxidation is commonly
observed and can be measured by the levels of reactive aldehyde species
including malondialdehyde (MDA) and 4-hydroxynonenal (HNE). In addition to
cellular dysfunction and mutagenic effects, oxidative stress induces the
production of proinflammatory cytokines and adhesion molecules (69) further
propagating systemic oxidative stress and inflammation under obese conditions.
In efforts to determine the initiating causes of hepatic steatosis, some
research has focused on the development of oxidative stress and mitochondrial
dysfunction. Not only has oxidative stress been implicated in the progression of
obesity and cardiometabolic dysfunction (97, 163), some rodent studies suggest
mitochondrial-dependent oxidative stress precedes the development of insulin
resistance in early stages of NAFLD pathogenesis (211). Rector et al.
demonstrated

that

obese-prone

OLETF

rats

exhibited

altered

hepatic

mitochondrial function and a pro-oxidative environment prior to the development
of NAFLD, suggesting that mitochondrial distress may be a casual mechanism as
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well as a consequence of hepatic metabolic dysfunction (211). In addition,
hepatic oxidative stress has been shown to consistently drive the progression of
diet-induced insulin resistance (163).
1.3.3 Contribution of Other Cell Types to NAFLD Development
Although hepatocytes are the primary cell type in the liver affected by lipid
accumulation, other cell types are present that have been implicated in the
pathophysiology of NAFLD. Kupffer cells are resident macrophages located in
the liver sinusoids. They contribute to the detoxifying functions of the liver by
quickly recognizing foreign or dangerous molecules and containing them for
degradation (206). Hepatic lipid has been shown to activate Kupffer cells through
a number of mechanisms. For example, ballooning of hepatocytes due to lipid
overload creates physical restriction on liver sinusoids reducing blood flow and
activating Kupffer cell-mediated inflammatory pathways (65). In addition, FFAs in
circulation can activate various cell membrane receptors, including members of
the toll like receptor (TLR) family, and induce the release of inflammatory
markers such as TNFα (125).
Another cell type that contributes to the progression of NAFLD to more
serious NASH is the hepatic stellate cells (HSCs). As a result of increased
proinflammatory cytokine secretion from Kupffer cells, HSCs become activated
and produce substantial amounts of extracellular matrix (ECM) including collagen
type I, fibronectin, and proteoglycans resulting in a significant remodeling of
cellular structure and stiffening of the liver tissue (289). In addition to fibrosis,
HSCs contribute to the proinflammatory environment by secreting additional
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cytokines that perpetuate hepatic fibrogenesis. Last, sinusoidal endothelial cells
have also been implicated in the pathology of NAFLD. Like other metabolic
diseases, NAFLD-associated endothelial dysfunction has been linked to impaired
vasoconstriction

and

vasodilation,

which

augments

the

progression

of

inflammation, oxidative stress, and fibrogenesis.
1.4 The Canonical NO/cGMP Signaling Pathway
The nitric oxide (NO) pathway has been considered a critical signaling
mechanism for maintaining vascular tone through the induction of vascular
smooth muscle cell relaxation and vasodilation. Within the past five years, the
effects of this signaling cascade have been broadened to include cellular
metabolism and energy homeostasis. NO, a gaseous signaling molecule, is
produced by a family of enzymes called nitric oxide synthases (NOSs) (181). The
first in the family, neuronal NOS (nNOS, NOS1), is exclusively expressed within
the central and peripheral nervous system. Inducible nitric oxide synthase (iNOS,
NOS2) is expressed largely in the immune cell population and produces
pathological levels of NO that contribute to a proinflammatory environment.
Endothelial nitric oxide synthase (eNOS, NOS3) was named for its high
expression level in endothelial cells and its role in vascular tone; however, other
studies have identified eNOS as the primary NOS isoform in a number of cell
types including adipocytes, hepatocytes, and skeletal muscle (166, 171, 244).
NO binds to the β1 subunit of soluble guanylyl cyclase (sGC), which includes the
heme prosthetic group and NO-binding domain. Once activated, sGC converts
guanosine monophosphate (GMP) to the active secondary messenger molecule
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cyclic GMP (cGMP) (57). In metabolic tissues, the effects of cGMP signaling are
primarily

facilitated

serine/threonine

through

protein

cGMP-dependent

kinase

responsible

protein
for

kinase

(PKG),

phosphorylating

a

several

intracellular targets modulating cellular functions (202).
1.4.1 Impacts of NO/cGMP Signaling on Metabolic Health
In vitro studies as well as several knockout and transgenic mouse models
have demonstrated the NO/cGMP signaling pathway is critical for maintaining
healthy cellular metabolism in insulin-responsive tissues. It has been clearly
demonstrated that cGMP promotes adipogenesis and mitochondrial biogenesis
in 3T3-L1 cells (immortalized murine preadipocyte cell line) and primary white
adipocytes through increased expression of adipogenic markers (171, 235, 304).
Some studies suggest that increased cGMP/PKG signaling enhances lipid
turnover (133) and drives UCP1-dependent energy expenditure contributing to a
browning phenomenon in white adipocytes (24, 171).
Similarly in brown adipose tissue, cGMP/PKG promotes brown adipocyte
proliferation and increases PPARγ and UCP1 expression (187). In loss-offunction studies, brown adipocytes isolated from PKG deficient mice had a
significant impairment in brown adipogenesis and UCP1-dependent thermogenic
potential (90). Similarly, newborn mice lacking PKG exhibit a significant reduction
in BAT mass suggesting PKG regulates BAT differentiation and function in vivo
(90). On the contrary, gain-of-function studies utilizing PKG transgenic mice
exhibit a leaner phenotype, increased mitochondrial biogenesis in BAT and
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skeletal muscle, and increased oxygen consumption driven by enhanced
mitochondrial respiration (172).
The effects of PKG overexpression in mice challenged with HF diet are
less conclusive. Miyashita et al. demonstrated that HF-fed male PKG transgenic
mice were protected from diet-induced obesity after just eight weeks of feeding
(172). Interestingly, Nikolic et al. saw female PKG transgenic mice, not males,
were protected from diet-induced obesity after 16-week diet challenge through
increased BAT-dependent energy expenditure (185). Although HF diet composed
of 60% kcal from fat were used for both studies, several factors could have
contributed to the conflicting reports including differences in mouse strains,
length of diet challenge, and temperature of housing conditions.
Numerous rodent studies and in vitro experiments have identified the
NO/cGMP/PKG signaling pathway as a therapeutic target for obesity and
obesity-associated diseases. Although support is strong for the role of cGMP
augmenting healthy metabolic function, the mechanisms contributing to both
impaired NO/cGMP synthesis and signaling in obese conditions have not been
fully defined. A handful of studies suggests increased reactive oxidative species
characteristic of cellular metabolic dysfunction competitively inhibit NOdependent activation of sGC (167, 245). Studies examining upstream regulators
of NO/cGMP signaling have not been explored under obese conditions. Future
studies are necessary to further elucidate mechanisms responsible for obesityinduced deregulation of NO/cGMP signaling.
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1.5 Thrombospondins: Multi-functional Signaling Molecules
Thrombospondins are a family of secreted matricellular glycoproteins that
serve no structural purpose, but are typically expressed in response to stress.
Thrombospondins 1-2 are homotrimers (three identical subunits) while 3-5 are
homopentamers (1). Each subunit consists of an N-terminal domain, central type
1 repeats, and a C-terminal domain, which are responsible for interacting with
various receptors (217). Within the family, thrombospondin 1 (TSP1; also
abbreviated Thbs1) has been most extensively studied. In 1971, Baenziger et al.
first isolated TSP1 from platelets treated with thrombin, deeming TSP1 a stress
response protein (13). Since then, TSP1 has been implicated in inflammatory
responses (152), apoptosis, and serves as a major regulator of angiogenesis
(101, 113). Further, TSP1 has been identified as the most potent activator of
latent transforming growth factor-β (TGF-β) (51).
Transcription of the TSP1 gene is positively regulated by a number of
pathways. Interestingly, hyperglycemia and hyperleptinemia, two hallmarks of
obesity and metabolic dysfunction, have been identified as positive regulators of
TSP1 transcription in a variety of tissues including tumors, vessel walls, cardiac
cells, and renal cells (42, 56, 247, 277, 306). Now, the effects of TSP1 are being
examined in a variety of cardiometabolic disorders including diabetes and obesity
development.
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1.5.1 Links Between Thrombospondin 1 (TSP1) and Metabolic
Dysfunction
Over the past twenty years, several studies have identified a pathological
role for TSP1 in the development of obesity and several of its associated
comorbidities. In 2000, Hida et al. first identified TSP1 as being one of thirteen
novel genes upregulated in visceral adipose tissue of obese, diabetic rats
compared to lean, non-diabetic controls (95). At that time, TSP1 was primarily
identified as a protein released from platelets in response to stress and as an
inhibitor of angiogenesis that could potentially contribute to cardiovascular
disease. From this study, evidence suggested adipose tissue was a source of
TSP1 in circulation. However, the cellular source of TSP1 within adipose tissue
was yet to be defined.
Following this study, Varma et al. confirmed TSP1 mRNA levels were
approximately four-fold higher in adipocyte fractions of human subcutaneous
adipose tissue compared to the stromal vascular fraction (endothelial cells,
preadipocytes, mesenchymal stem cells, immune cell population) (268). Further,
significant positive correlations between human subcutaneous adipose tissue
mRNA levels of TSP1 and body mass index (BMI), circulating inflammatory
cytokines, and adipose tissue-specific inflammatory markers were observed
(268). From these studies, it was concluded that TSP1, a novel adipokine, may
contribute to systemic effects of obesity and other peripheral metabolic
complications. Further studies by Matsuo et al. showed that TSP1 expression
was significantly higher in human visceral adipose tissue compared to
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subcutaneous adipose tissue depots and that TSP1 levels positively correlated
with BMI, abdominal obesity, and hyperglycemia (162). These findings further
supported the idea that robust TSP1 secretion from visceral adipose tissue may
mediate global metabolic dysfunction through direct access to systemic
circulation via the portal vein.
Several diet-induced obesity studies utilizing whole body TSP1 deficient
mice have been completed to further investigate the role of TSP1 in the
development of diet-induced body weight gain, inflammation, and insulin
resistance. From these studies, there have been discrepancies in whether TSP1
deficiency regulates adiposity in a diet-induced obesity paradigm. Li et al.
demonstrated that after 16 weeks of HF diet challenge (60%kCal from fat) TSP1
deficient mice were not protected against diet-induced body weight gain or fat
mass accumulation compared to HF-fed wildtype controls (144). Similarly,
another group demonstrated no difference in body weight gain in TSP1 deficient
and wildtype control mice after 15 week diet challenge (42% kCal from fat) (274).
On the other hand, two independent studies observed attenuated weight gain
after 20 weeks of diet challenge (45% and 60% kCal from fat) in TSP1 deficient
male mice compared to controls (100, 128). Differences in studies have been
attributed to various lengths of diet challenge, inconsistent fat content in the diet,
and the multiple interactions TSP1 has with a variety of tissues.
Although contradictions in body weight gain have been observed in TSP1
deficient mice, several protective phenotypes have been consistent across
studies. First, TSP1 is tightly associated with the development of systemic and
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adipose tissue-specific obesity-associated inflammation. Independent of body fat
mass, TSP1 deficiency reduces macrophage accumulation within white adipose
tissue depots demonstrated by reduced positive Mac2 (100, 128) and F4/80
staining (144). Further, mRNA levels of TNFα, an immunogenic trigger for
metabolic dysfunction, were significantly reduced in white adipose tissue of HFfed TSP1 deficient mice (128, 144). In efforts to further characterize the effects of
TSP1 on systemic inflammation, Li et al. demonstrated a significant reduction in
TNFα, interleukin-6 (IL-6), MCP1, and the metabolic syndrome biomarker,
plasminogen activator inhibitor-1 (PAI-1) in circulation (144). In addition, bone
marrow derived macrophages isolated from HF-fed TSP1 deficient mice
demonstrated reduced macrophage migration upon stimulation with both
lipopolysaccharide (LPS) and MCP1 compared with macrophages isolated from
wildtype controls (144). Together, these data strongly suggest TSP1 plays a role
in macrophage migration and infiltration into white adipose tissue in obesity as
well as serving as a contributor to the systemic proinflammatory state associated
with diet-induced obesity.
In addition to inflammation, TSP1 deficiency improves glucose tolerance
and insulin sensitivity in diet-induced obese rodent models. Multiple studies have
determined that TSP1 deficient mice exhibit reduced plasma insulin levels while
maintaining similar glucose levels, suggesting less insulin is required to stimulate
glucose disposal (128, 144). Similarly, hyperinsulinemic euglycemic clamp
studies confirmed HF-fed TSP1 deficient mice required significantly higher levels
of glucose infusion to maintain the same plasma blood glucose levels as controls
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supporting the idea TSP1 deficiency enhances glucose tolerance (100).
Additional studies have confirmed enhanced insulin-dependent glucose disposal
was specific to skeletal muscle and not adipose tissue (100). Studies are lacking
in determining the effects of TSP1 deficiency on hepatic glucose tolerance and
insulin sensitivity.
Not only has TSP1 been implicated to play a role in inflammation and
insulin resistance, several studies have examined other obesity-associated
comorbidities

including

renal

dysfunction,

cardiovascular

disease,

and

hypertension. Maimaityiming et al. determined renal TSP1 expression contributes
to fibrosis and obesity-induced hypertension (155). In addition, TSP1 is a critical
regulator of vascular tone by inhibiting endothelial-dependent vascular smooth
muscle cell relaxation (18, 106). TSP1 expression also correlates with
cardiovascular disease risk and promotes inflammation in both atherosclerosis
and abdominal aortic aneurysm rodent models (150, 154, 239).
Overall, the role of TSP1 expression in adipose tissue could be attributed
to paracrine effects necessary for promoting ECM remodeling, adipose tissue
expansion, and lipid loading. As a consequence, systemic effects on other
tissues occur because of robust TSP1 secretion in obese conditions.
Unfortunately, the mechanisms facilitating these actions are still unknown and
require further investigation. Several interactions have been identified that
facilitate the actions of TSP1, including extracellular matrix proteins, integrins,
CD36, and CD47 (177). Of these, TSP1 binds to CD47 most potently – activating
CD47 at picomolar concentrations (physiological levels) (102, 107). In addition,

29

TSP1 binding to other receptors, such as CD36, requires the presence of CD47
(107, 170) suggesting this specific receptor is critical for regulating multiple
TSP1-dependent intracellular signaling cascades in a variety of tissues.
1.6 CD47: Potent Receptor to TSP1
CD47 is an integral glycoprotein cell receptor and is classified in the
immunoglobulin superfamily (160). CD47 consists of an extracellular IgV domain,
which may be heavily glycosylated and a variably spliced cytoplasmic sequence
(118, 242). Because of the post-translational modifications possible, the
molecular weight of CD47 ranges from 45-55kDa (198). When CD47 was first
identified, it was laterally associated with integrins in the cellular membrane (27),
earning it the name integrin-associated protein (IAP), which is still used in some
literature to date. Over the past several decades, CD47 has been observed in
several other interactions and therefore is used more widespread than its original
name, IAP (28, 193).
1.6.1 Structure and Functions of CD47
This cellular receptor contains 5 membrane-spanning domains with
multiple disulfide bonds necessary for signaling as demonstrated in Figure 1.3 –
one being between the extracellular loop of transmembrane domains 4 and 5 and
the N-terminus (164) and the extracellular loop of transmembrane domains 1 and
the IgV domain (210).

The amino acid sequence of CD47 is moderately

conserved between many species with approximately 60-70% homology shared
between humans, mice, rats, and bovine (28, 193). More specifically, mice and
rats have approximately 84% homology in their amino acid sequences (250). The
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C-terminal cytoplasmic tail can be variably spliced into four common isoforms,
ranging from 3-36 amino acids (147, 212). The second shortest of the four
isoforms with a 16-amino acid long cytoplasmic tail is the most dominant form
(212) No sequence motif on the cytoplasmic tail has been identified that exhibits
any catalytic activity (28).
Literature examining the regulation of CD47 expression is severely
lacking. In tumor cells, CD47 protein expression is significantly upregulated and it
has been widely accepted that increased expression acts as a pathological,
inhibitory signal for immune cell phagocytosis (110), which impairs the ability of
the innate immune system to attack and remove diseased cells. Several
transcriptional regulators have been recently identified to regulate this
phenomenon.

MYC, Hypoxia-inducible factor 1 (HIF1), and a-Pal/nuclear

respiratory factor 1 (NRF1) have all been shown to bind to the promoter region of
CD47 and induce CD47 gene expression in a number of cancer cell lines (36, 40,
303). Interestingly, just this year Lo et al. demonstrated that CD47 gene
expression was tightly upregulated by the proinflammatory nuclear factor κ B
(NFκB) signaling pathway in vivo and in vitro hepatocellular carcinoma models
(151). These studies suggest that transcriptional regulation of CD47 expression
is cell-type and condition specific. To date, no other studies have been
completed to examine the transcriptional or translational regulation of CD47
expression in healthy tissues or in any other disease states besides cancer
models.
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CD47 expression can be seen in various tissues and cell types throughout
the body, ranging from microglia to red blood cells (28, 193). Relative mRNA
levels of CD47 are observed in a variety of tissues. In addition, expression levels
are not impacted by 4-month high fat diet challenge in mice, as demonstrated in
Figure 1.4. Ubiquitous expression suggests that CD47 is active or necessary in
several different cellular pathways, mechanisms, and interactions. Many wellestablished functions are associated with immunity, self-recognition, cellular
adhesion, and vascular tone (242) and are dependent on the ligand or partner
receptor associated with CD47. Interestingly, literature suggests that all effects of
CD47 activation on intracellular signaling are dependent on activation by the
matricellular proteins, thrombospondins – specifically TSP1.
1.6.2 Downstream Signaling Effects of TSP1-CD47 Interaction
Depending on the tissue or cell type, TSP1 activation of CD47 exhibits a
variety of effects on intracellular signaling. In endothelial cells, it has been clearly
demonstrated that TSP1 binding to CD47 inhibits intracellular calcium flux and
subsequently the activation of endothelial nitric oxide synthase (eNOS, NOS3)
(18), the enzyme responsible for physiological levels of nitric oxide (NO)
production. Another well-defined effect of the TSP1-CD47 interaction is the
regulation of cyclic nucleotide synthesis and signaling. Less studied are the
effects of CD47 activation on cellular levels of cyclic adenosine monophosphate
(cAMP). It has been shown that CD47 deficiency is associated with elevated
cAMP levels in vascular, skeletal, and cardiac muscle cells, as well as whole
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heart tissue, and that these effects involve G-coupled protein receptors to alter
the activation of adenylyl cyclase (AC) (106, 297).
Further, CD47 has been shown to redundantly suppress NO/cGMP
synthesis and signaling in a variety of tissues, as depicted in Figure 1.5. First, as
previously mentioned, suppression of intracellular calcium reduces the ability of
eNOS to produce NO from arginine, which is necessary to stimulate activation of
sGC (18). Second, CD47 inhibits the phosphorylation of sGC necessary to
convert GMP to cGMP (207). And third, CD47 inhibits the ability of cGMP to
activate PKG (108). It is well established that NO/cGMP signaling plays a critical
role in regulating vascular tone, enhancing blood flow, and promoting
angiogenesis (216). Recent studies have begun to demonstrate that this
signaling cascade is also critical for functions in metabolic tissues and could have
broad implications on nutrient homeostasis and mitochondrial function in obese
conditions.
1.6.3 Other Characterized Interactions of CD47
In addition to thrombospondins, integrins and signal regulatory proteins
(SIRPs) uniquely interact with CD47. It has even been shown that all CD47
interactions compete for similar binding sites on the extracellular IgV domain of
CD47 (102). These characterized interactions regulate a diverse host of cellular
processes including cellular adhesion, stress response, and cell survival.
1.6.3.1 Integrins
Integrins serve as a regulatory protein for cell-cell or cell-extracellular
matrix interactions by interacting with a host of cell membrane receptors,
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structural proteins or ECM molecules. Integrins are transmembrane receptors
comprised of heterodimers and are expressed on all cell types including
erythrocytes and platelets (28). As mentioned previously, CD47 was initially
identified as integrin-associated protein (IAP). Rather than a cell-cell interaction,
CD47 has been shown to laterally associate with specific integrins in a cis
interaction within the same plasma membrane forming a large signaling complex
(28) and that cholesterol-rich portions of the plasma membrane, also known as
lipid rafts, are necessary to stabilize the complex (85). Out of the large family of
integrins, αvβ3 and α2β1 have been consistently copurified with CD47 from a
variety of cell types including smooth muscle cells, erythrocytes, and platelets
(77, 278). To demonstrate how CD47 activation induces integrin function, when
CD47 is activated by ligands, integrin-mediated cell migration and adhesion are
induced. For example, TSP1 binds CD47 and subsequently modulates αvβ3
function in human umbilical vein endothelial cells (HUVECs), C32 cells, and
tumor cells by promoting chemotaxis and cellular migration (15, 38, 39, 77). Both
CD47 and integrins are widely expressed; therefore, additional studies are
necessary to fully understand the partnership and functions of this complex in
specific cell types.
1.6.3.2 Signal Regulatory Proteins (SIRPs)
Another highly characterized interaction with CD47 is a member of the
signal regulatory protein (SIRP) family, SIRPα (commonly identified as SHPS1
and CD172a). Interestingly, CD47 and SIRPα exhibit very different tissue
expression profiles. SIRPα expression is restricted to neuronal populations and
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myeloid-lineage hematopoietic cells including macrophages and immature
dendritic cells (4, 266), whereas CD47 is ubiquitously expressed throughout the
body (176). In 2000, Oldenborg et al. determined SIRPα expressed on myeloidlineage hematopoietic cells interacts with CD47 as a partner receptor to inhibit
phagocytosis (195). This receptor-receptor interaction acts as a mechanism to
establish self-recognition, especially with red blood cells and macrophages.
Wildtype mice transfused with CD47 deficient red blood cells saw rapid clearance
by phagocytosis from the bloodstream (194, 195), suggesting CD47 regulates
the half-life of red blood cells in circulation by providing a “don’t eat me” signal to
macrophages and dendritic cells.
CD47 and SIRPα have also shown increased expression in corresponding
regions of the brain, suggesting their partnership may play a role in the central
nervous system. Studies suggest CD47 and SIRPα may be involved in memory
formation, stress response, and autonomic nervous system function (8, 98, 173).
Limited evidence in rodent models and cell culture systems suggest CD47 and
SIRPα play specific roles in the brain. No studies have been completed that fully
elucidate the relationship of these two receptors in neuronal function. Future
studies are warranted to fully determine the role of CD47 and SIRPα in neuronal
survival and stress response.
1.7 Statement of the Problem
Metabolic dysfunction in obese conditions is incredibly complex; however,
several central underlying pathways have been identified which include the
development of proinflammatory and poor oxidative cellular environments.
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Increased reactive oxidative species and activated stress response signaling
pathways in tissues with high metabolic activity perpetuates a systemic
proinflammatory environment, which ultimately results in insulin resistance and
dyslipidemia. Some suggest identifying mechanisms that augment inflammation,
oxidative stress, and mitochondrial dysfunction in metabolic tissues could be a
viable therapeutic target for obesity and its associated complications. It is critical
that pathways contributing to metabolic abnormalities are identified so that new
therapeutics for obesity and its associated complications may be developed.
The receptor, CD47, is ubiquitously expressed throughout the body. Its
expression has been implicated to serve a pathological role in the progression of
inflammation and oxidative stress in a number of conditions including
cardiovascular disease, pulmonary hypertension, ischemia reperfusion, and
transplantation models. Further, it has been well established that the most potent
ligand of CD47, TSP1, plays a critical role in facilitating inflammation and
metabolic dysfunction in diet-induced obesity. Some previous studies have
alluded to the role of CD47 in regulating mitochondrial function, yet no studies
have examined the effects of CD47 in diet-induced obesity and its associated
comorbidities. We believe the studies included in this dissertation identified novel
regulatory roles for CD47 within metabolic tissues.
For our studies, we used both global TSP1 deficient mice and global
CD47 deficient mice in a high fat diet-induced obesity paradigm. The central
hypothesis of these studies is that CD47 contributes to obesity-associated
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metabolic dysfunctions through diverse mechanisms including inflammation,
energy utilization, and TSP1-mediated oxidative stress.
We know TSP1 expression is upregulated under obese conditions and
that TSP1 contributes to obesity-associated inflammation and impairments in
glucose homeostasis, but it is unclear how these actions are facilitated. With
CD47 being the most potent cell membrane receptor for TSP1, we will explore
whether TSP1 activity is mediated by CD47 activation. We hypothesized that lack
of CD47 will protect against obesity-associated inflammation and will preserve
healthy glucose homeostasis despite high fat diet challenge.
It is also well established that cGMP/PKG signaling is critical for healthy
adipocyte function, mitochondrial respiration, and energy homeostasis, yet this
signaling pathway is significantly impacted by high fat diet-induced obesity. The
mechanisms contributing to this impaired signaling is unknown. Because CD47
activation has been shown to redundantly suppress cGMP/PKG signaling,
studies were conducted to examine whether CD47 regulates energy homeostasis
in metabolic tissues. We hypothesized that CD47 deficiency would enhance
mitochondrial function and preserve energy homeostasis. The following aims
were designed to test our hypotheses:

Specific Aim 1: To characterize the global effects of CD47 deficiency on dietinduced obesity in a rodent model
A. To determine whether CD47 augments obesity-associated systemic
and adipose tissue-specific inflammation
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B. To define the relative role of CD47 in energy homeostasis within
metabolic tissues under obese conditions

Increased oxidative stress has been shown to be the molecular link
between mild steatosis and progression to more severe non-alcoholic
steatohepatitis
inflammation,

through
and

induction

fibrogenesis.

of

cellular

stress

Unfortunately,

the

signaling
exact

pathways,

mechanisms

augmenting reactive oxidative species production have not been clearly
elucidated. The TSP1-CD47 signaling axis has previously been implicated in the
development of hepatic oxidative stress and inflammation in other diseased
conditions (hepatic ischemia/reperfusion injury, liver transplantation models), yet
its contribution to fatty liver-induced ROS has never been explored. In vivo
studies with two mouse models and in vitro experiments will define the
contribution of TSP1-CD47 signaling to hepatic oxidative stress in a nonalcoholic fatty liver rodent model. We hypothesize that TSP1-CD47 activity leads
to increased hepatic oxidative stress within a fatty liver model. The following aim
was designed to test our hypothesis:

Specific Aim 2: To define the contribution of the TSP1-CD47 axis in the
development of non-alcoholic fatty liver disease-associated oxidative stress
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1.7.1 Impact
We demonstrate that CD47 deficiency is protective against adiposity,
insulin resistance and obesity-associated chronic inflammation. Further, lack of
CD47 corresponds with increased energy expenditure in vivo and in vitro.
Additional studies show that reduced TSP1-CD47 signaling may be protective
against hepatic oxidative stress and the pathogenesis of NAFLD. As a cell
membrane receptor, CD47 may be a viable therapeutic target to reduce obesityassociated oxidative stress, inflammation, and mitochondrial dysfunction.
Currently, four clinical trials (NCT02678338, NCT02641002, NCT02367196,
NCT02663518) are underway using monoclonal functional blocking antibodies
against CD47 as a cancer immunotherapy. Our studies provide new evidence
that targeting CD47 could be expanded to include metabolic disorders.
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Table 1.1 Comparison of white and brown adipose tissues
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Figure 1.1 Adipose tissue remodeling and inflammation.
Modified cartoon depiction of the effects of obesity on adipose tissue as
previously illustrated (223). Adipocytes are dynamic cell types capable of
dramatically expanding cell size to accumulate excess lipid. As adipocytes
hypertrophy, stress is placed on the ECM resulting in an inflammatory response.
Adipocytes and ATMs are capable of secreting proinflammatory proteins,
cytokines and chemokines, to stimulate an immune response and recruit
additional macrophages to the adipose tissue depot. This mechanism further
propagates the inflammatory phenotype commonly observed in obesity and
contributes to adipocyte cell death and whole body insulin resistance.
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Figure 1.2 Relationship between obesity and systemic complications.
Obesity contributes to metabolic dysfunction in peripheral tissues and ultimately
results in increased risk of type 2 diabetes and cardiovascular disease. Adapted
schematic diagram of the relationship between obesity and global metabolic
dysfunction as previously illustrated (261).
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Figure 1.3 Molecular structure of CD47
Modified cartoon depiction of the structure of CD47 (200). CD47 is a unique cell
membrane receptor which exhibits both an IgV immunoglobulin domain and 5
membrane-spanning domains with multiple disulfide bonds necessary for
signaling. The C-terminal cytoplasmic tail can be variably spliced into four
common isoforms, ranging from 3-36 amino acids. Of these four isoforms, the
second shortest C-terminal cytoplasmic tail (16 amino acids) is the most
commonly observed form.
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Figure 1.4 Dietary regulation of CD47 mRNA levels in a variety of tissues
Tissue expression profile of CD47 mRNA levels after four months of either LF or
HF diet challenge. Expression levels demonstrate no significant diet regulation of
CD47 mRNA levels.
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Figure 1.5 TSP1-mediated activation of CD47 on intracellular signaling
Cartoon depiction of intracellular signaling as previously illustrated (218, 219).
First, CD47 activation via TSP1 inhibits the phosphorylation of eNOS (at
Ser1177) to produce NO from arginine. Second, CD47 inhibits the NO-mediated
activation of sGC necessary to convert GMP to cGMP. And third, CD47 blunts
the ability of cGMP to activate PKG. This canonical signaling cascade has been
implicated in vascular tone and vasodilation; however, recent studies suggest its
regulation in mitochondrial function, energy homeostasis, and obesity-associated
inflammation could expand its therapeutic potential to metabolic diseases.
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Section 2: METHODS
2.1 Breeding and Genotyping
CD47-/- and wildtype (WT/CD47+/+) littermate controls were generated by
breeding heterozygous CD47+/- mice. At approximately two weeks of age, pups
were sexed and tail clips were collected for genotyping. DNA was extracted from
tail clips using the E.Z.N.A. Tissue DNA Kit (Omega Bio-Tek, Norcross, GA,
USA). For genotyping, two specific polymerase chain reaction (PCR) products
must be examined per mouse – wildtype (300 base pairs) and mutated (199 base
pairs). PCR mixes were prepared using the Kapa 2G Fast HotStart PCR Kit with
dNTPs (Kapa Biosystems, Wilmington, MA, USA), common primer 7714, and
either wildtype primer 13700 or mutant primer 7297. Primer sequences can be
found in Table 2.1. Following PCR, samples were loaded with a 6x Blue/Orange
Loading Dye (Promega, Madison, WI, USA) and run on a 2% agarose gel with
ethidium bromide with a 100 base pair DNA Ladder (Promega, Madison, WI,
USA). Gels were imaged using the PXi Multi-Application Gel Imaging system
(Syngene, Frederick, MD, USA). Wildtype samples demonstrated one band at
300 base pairs. Mutant (CD47-/-) mice exhibited one band at 199 base pairs.
Heterozygous mice present bands at both 300 and 199 base pairs.
2.2 Animal Experimental Protocols
All experiments involving mice conformed to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and were approved by
the University of Kentucky Institutional Animal Care and Use Committee.
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2.2.1 Aim 1
All experiments were performed on eight week-old male CD47 deficient
mice (C57BL6/J background from Jackson Laboratories) and same sex and agematched C57BL6/J controls (purchased from Jackson Laboratories). Mice were
given a high fat (HF) (60% kcal from fat; D12492, Research Diets, Inc., NJ) or
low fat (LF) diet (10% kcal from fat; D12450B; Research Diets, Inc., NJ) for 16
weeks with standard laboratory water. Each group contained 7 mice. Body
weight was measured weekly at the same time. Temperature transponders
(Implantable Programmable Temperature Transponder 300; BioMedic Data
Systems, Seaford, DE) were subcutaneously implanted into mice at the week 8
time point during diet challenge. The wireless reader system was utilized to
measure core body temperatures in both the light and dark cycles. At the end of
the study, mice were sacrificed. Blood was collected and adipose tissue depots,
liver, and muscle were harvested for various analyses.
2.2.2 Aim 2
To examine hepatocyte-specific expression of CD47 after HF diet
challenge, C57BL6/J mice (Jackson Laboratories) were fed either a high fat (HF)
(60% kcal from fat; D12942, Research Diets, Inc., NJ) or low fat (LF) diet (10%
kcal from fat; D12450B; Research Diets, Inc., NJ) for the designated time frame
(3, 7, or 14 days) with standard laboratory water. Each group contained 3 mice.
Mice were sacrificed and hepatocytes were isolated as described by the two-step
perfusion method (see details in Section 2.16.2) (112).
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To examine the effects of TSP1 deficiency on the development of NAFLD,
eight week old male TSP1 deficient and littermate wildtype controls (WT; on
C57BL6/J background from Jackson Laboratories) were challenged with high fat
(HF) (60% kcal from fat; D12942, Research Diets, Inc., NJ) or low fat (LF) diet
(10% kcal from fat; D12450B; Research Diets, Inc., NJ) for 16 weeks with
standard laboratory water. For studies, each group contained 10-15 mice.
To examine the effects of CD47 deficiency on the development of NAFLD,
eight week-old male CD47 deficient mice and littermate wildtype controls (WT;
C57BL6/J background from Jackson Laboratories) were utilized for all
experiments. CD47-/- and wildtype (WT/CD47+/+) littermate controls were
generated by breeding heterozygous CD47+/- mice. Mice were fed either a HF
or LF diet for 16 weeks with standard laboratory water. Each group contained 711 mice. Body weights were measured weekly at the same time. At the end of all
studies, mice were sacrificed. Blood and liver tissue were collected for various
analyses.
2.3 Indirect Calorimetry and Body Composition
Mice were individually housed in TSE LabMaster chambers (TSE
Systems, Inc., Midland, MI, USA) for 5 days for measurement of food intake,
water intake, and indirect calorimetry. Body composition including lean and fat
mass was measured by EchoMRI (Echo Medical System, Houston, TX, USA)
basally and two weeks prior to the end of the studies.

48

2.4 In Vivo Lipolysis Assay
Eight week old CD47 deficient and wildtype littermate control mice were
fasted for six hours and then treated with either CL 316,243 (β-agonist; 1mg/kg
BW; i.p. injection) or saline (vehicle) as control. Blood was collected via tail vein
15 minutes post injection and plasma glycerol was measured with Free Glycerol
Reagent and appropriate standards (Sigma, St. Louis, MO, USA). Each group
contained 4-7 mice.
2.5 Ex Vivo Lipolysis Assay
Subcutaneous adipose tissue (SAT), epididymal adipose tissue (EAT),
and brown adipose tissue (BAT) were excised from eight week old CD47
deficient and wildtype littermate control mice after a six hour fast. Tissue was
weighed and kept in ice cold PBS until all tissue was collected. Adipose tissue
(80-180mg) was placed in one well of a 24-well plate (n=3 mice/group; all tissue
samples from each mouse were triplicated). Tissues were serum starved in
Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Carlsbad, CA, USA)
supplemented with 1% fatty acid-free bovine serum albumin (BSA) for 1 hour at
RT. Tissue was then treated with Krebs Ringer Buffer (125mM NaCl, 5mM KCl,
1.8mM CaCl2, 2.6mM MgSO4, 5mM HEPES, pH adjusted to 7.2) in the presence
of vehicle or isoproterenol (10µM, Sigma, St. Louis, MO, USA) as previously
described (87). After 2 hours, media was collected to measure glycerol release
with the Free Glycerol Reagent and appropriate standards (Sigma, St. Louis,
MO, USA). Values were normalized to gram tissue weight.
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2.6 Plasma Parameters
Plasma insulin, IL-6, TNFα, IL-10, leptin, and MCP1 (eBioscience, San
Diego, CA, USA) were measured by ELISA. Plasma and liver TGs, non-esterified
fatty acids (NEFA) and total cholesterol (Wako Chemicals, Richmond, VA, USA)
levels were measured enzymatically. Plasma ALT levels were measured by
colorimetric kit from BioAssay Systems (Hayward, CA, USA).
2.7 In Vivo Glucose Tolerance/Insulin Sensitivity Assays
Glucose tolerance and insulin tolerance were analyzed basally and after
15-weeks of HF or LF feeding. Mice were fasted 6 hours before intraperitoneal
injections of glucose (1 g/kg body weight) or insulin (0.5 unit/kg body weight;
Novolin R, Novo Nordisk Inc., Plainsboro, NJ, USA). Blood glucose
concentrations were measured using a glucometer at 0, 15, 30, 60, and 120
minutes post injection.
2.8 Tissue Histology
Interscapular brown adipose tissues, white adipose tissue depots, and
liver tissue from all four groups of animals were embedded in paraffin, sectioned
at 4μm, and stained with hematoxylin and eosin-stain (H&E) or Sirius Red for
fibrosis by standard method through the University of Kentucky Pathology Core
services from the Center of Research in Obesity and Cardiovascular Disease
(COCVD). All images were acquired with a Nikon Eclipse 55i microscope at 20x
objective. Image threshold features of Nikon NIS Elements BR software (Melville,
NY, USA) were utilized to quantify percent of total area positively stained with
Sirius Red. Four sections per mouse and three mice per group were measured.
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Adipocyte area was quantified using the Object Count feature of Nikon NIS
Elements BR software (Melville, NY, USA). Forty adipocytes were measured per
section (n=3 sections/mouse) from mice in all four groups (n=3 mice/group).
2.9 Immunohistochemistry
Epididymal adipose tissue and liver was fixed and embedded in paraffin.
Paraffin-fixed tissues were cut into 4μm sections and placed onto slides.
Sections were deparaffinized, rehydrated in graded mixtures of ethanol/water,
pretreated by boiling in citrate buffer (pH 6.0), and endogenous peroxidase
activity was blocked with 3% H2O2 for 30 min at room temperature (RT). The
sections were blocked for 1 hour at RT in 3% BSA in phosphate buffered saline
(PBS) (blocking solution) and immediately incubated with a rat anti-mouse F4/80
antibody (1:200 dilution; AbD Serotec, Raleigh, NC, USA) in blocking solution for
1 hour at RT. Then, slides were washed, incubated with biotinylated secondary
antibody for 30 min, and then washed again with PBS. Finally, peroxidase
substrate diaminobenzidine (Vector Lab, Burlingame, CA, USA) was applied and
incubated for 30 min. The slides were rinsed and counterstained with
hematoxylin. Mounting solution and coverslips were added. Images were
acquired with a Nikon Eclipse 55i microscope.
2.10 Liver Oil Red O Staining
Frozen liver tissues were cryostat sectioned at 6μm and fixed in 4%
paraformaldehyde in PBS for 10 min at RT. Working Oil Red O solution was
prepared by mixing 3 volumes of 0.5% Oil Red O in 100% isopropanol with 2
volumes distilled water and filtering through Whatman 4 filter paper. Slides were
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blotted in 60% isopropyl alcohol for 5 min, and then stained with working Oil Red
O solution for 15 min at RT. Slides were rinsed once with distilled water,
mounted, and cover slipped with warmed glycerol gelatin. Images were acquired
with a Nikon Eclipse 55i microscope.
2.11 Liver Triacylglycerol Levels
For analysis of liver TG content, approximately 50 mg of liver was placed
into 500μL of chilled Krebs Ringer Phosphate (118mM NaCl, 5mM KCl, 13.8mM
CaCl2, 1.2mM MgSO4, 0.016% KH2PO4, 0.211% NaHCO2) and each sample was
sonicated ten times (30 seconds/time). The homogenate was centrifuged at
2,000 × g for 10 min at 4°C, and 10μL of the supernatant was then removed for
triglyceride analyses. Triglyceride content was measured using Wako triglyceride
kit (Richmond, VA, USA).
2.12 Macrophage Migration Assay
Bone-marrow derived cells were isolated from femurs and tibias of male
WT and CD47 deficient mice fed with HF diet. These cells were cultured 7 days
in RPMI-1640 media containing 20% fetal bovine serum (FBS), 25 ng/ml M-CSF
(Sigma, St. Louis, MO, USA), and penicillin/streptomycin to allow differentiation
into mature macrophages. Ability of these macrophages to migrate toward MCP1 (50 ng/ml) was determined using modified Boyden Microchemotaxis Chamber.
Briefly, cells were washed twice with PBS, counted and loaded into the upper
chambers of a Transwell, while the lower chambers were filled with DMEM media
with or without MCP-1 (50 ng/ml). Transwell plates were then incubated at 37°C
for 6 hours. The upper inserts with membrane were removed and fixed in cold
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methanol and stained with crystal violet (Sigma, St. Louis, MO, USA). Cells were
counted from five different fields for each well. Results were expressed as a
migration index under the high magnification field.
2.13 cGMP Measurements
cGMP levels in brown fat or skeletal muscles from LF or HF fed WT or
CD47 deficient mice were measured by using the cGMP Direct Immunoassay Kit
(Colorimetric) from Biovision (Milpitas, CA, USA). Frozen tissues were
homogenized and the supernatant was collected. cGMP levels in the supernatant
were measured and calculated based on the cGMP standard curve following the
instruction manual.
2.14 Real-time Quantitative PCR (qPCR)
Total RNA from frozen adipose tissue, skeletal muscle, liver, and cells
were extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA was
reverse transcribed to cDNA by High Capacity cDNA Reverse Transcription Kit
(Invitrogen, Carlsbad, CA, USA). Real-time quantitative PCR was performed on a
MyiQ Real-time PCR Thermal Cycler with iTaq Universal SYBR Green Supermix
from Bio-Rad (Hercules, CA, USA). Relative mRNA expression was calculated
using the MyiQ system software as previous reported (144) and normalized to
18s RNA levels. All primers used to examine gene expression were designed
and purchased using the PrimerQuest Tool from Integrated DNA Technologies
(Coralville, IA, USA). All primer sequences utilized in this study are found
in Table 2.1.
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2.15 Mitochondrial DNA (mtDNA) Copy Number
DNA was extracted from skeletal muscle and brown adipose tissue by
using QIAamp DNA mini kit (Qiagen, Hilden, Germany). The relative
mitochondria DNA (mtDNA) copy numbers were determined by real-time PCR as
described previously (156) and normalized to nuclear DNA (nDNA/28s). Primer
sequences utilized are shown in Table 2.1.
2.16 Western Blotting
Brown fat, skeletal muscle, liver tissue, and cells were homogenized in
RIPA buffer (Sigma, St. Louis, MO, USA) plus protease and phosphatase
inhibitors (Pierce, Waltham, MA, USA). After concentrations were measured
using a BCA Assay (Pierce, Waltham, MA, USA), 30μg protein/well was
subjected to SDS-PAGE gel under reducing conditions and transferred onto a
nitrocellulose membrane. After blocking, the membrane was incubated with antiGAPDH (1:5000 dilution; Millipore, Billerica, MA, USA), anti-β-actin (1:5000
dilution; Santa Cruz, Dallas, TX, USA), anti-CD47 (1:1000 dilution; Abcam,
Cambridge, MA, USA), anti-TSP1 (1:1000 dilution; BD Biosciences, San Jose,
CA, USA), and anti-PKG-I (1:1000 dilution; BD Biosciences, San Jose, CA, USA)
antibodies at 4°C overnight. After washing, the membrane was incubated with
horseradish peroxidase-conjugated secondary antibodies (Jackson Labs, Bar
Harbor, ME, USA). The reaction was visualized by using an enhanced
chemiluminescence system (Pierce, Waltham, MA, USA). Immunoblots were
analyzed by scanning densitometry and quantified by Quantity One gel Analysis
software (Bio-Rad, Hercules, CA, USA).
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2.17 Tissue-level ROS Quantification
Hepatic oxidative stress was determined by the conversion of 2’7’dichlorofluorescein diacetate (H2DCFDA; Life Technologies, Carlsbad, CA, USA)
to the fluorescent label 2’7’-dichlorofluorescein (DCF) in tissue homogenates.
Frozen liver tissue was homogenized in 5 volumes of ice cold PBS and
centrifuged at 10,000 x g for 10 minutes at 4°C. Supernatants were mixed with
equal volume H2DCFDA (20µM in DMSO) and placed in a flat-bottom microplate.
Presence of the fluorescent probe DCF was measured after 10 minutes with a
fluorescent plate reader (BioTek Synergy H1 Hybrid Reader, Winooski, VT, USA)
at 485nm excitation and 520nm emission. Levels of lipid peroxidation were
measured in liver tissue homogenates using the Lipid Peroxidation (MDA) Kit
from Sigma (St. Louis, MO, USA). Approximately 10mg of tissue was used
according to the manufacturer’s protocol.
2.18 Cell Culture Models
2.18.1 HepG2 Cells
HepG2 cells, a human hepatoma cell line, were obtained from American
Type Culture Collection (ATCC) and cultured in Minimum Essential Medium
(MEM, Gibco, Carlsbad, CA, USA) supplemented with 10% FBS, 1% sodium
pyruvate, and 1% penicillin-streptomycin at 37°C with 5% CO2. For cellular ROS
quantification, cells were seeded at a density of 2x10 4 cells/well of a 96-well flat
bottom culture plate.
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2.18.2 Primary Murine Hepatocytes
Murine primary hepatocytes were isolated by the two-step perfusion
method (85).

First, livers were perfused with Ca2+/Mg2+-free HBSS

supplemented with 10mM glucose, 10mM HEPES, and 0.3mM EDTA. Second,
livers were digested with HBSS supplemented with 0.05% collagenase type IV
(Catalog No. C5138, Sigma, St. Louis, MO, USA), 1.3mM CaCl2, 0.5mM MgCl2,
10mM glucose, and 10mM HEPES. Hepatocytes were washed three times with
low speed centrifugation at 50 x g for 2 minutes. Cell viability was determined
with trypan blue staining (>90% cell viability) and were seeded in 96-well flat
bottom culture plates pre-coated with rat tail collagen at 2x104 cells/well and
cultured in Williams’ Medium E (Gibco, Carlsbad, CA, USA) supplemented with
10% FBS, 2% penicillin-streptomycin, 1% sodium pyruvate, 1% L-glutamine, and
1% insulin-transferrin-selenium at 37°C with 5% CO2.
2.18.3 3T3-L1 Cells
3T3-L1 mouse preadipocytes were obtained from American Type Culture
Collection (ATCC) and cultured in DMEM (Gibco, Carlsbad, CA, USA)
supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C with 5%
CO2. Once cells were 100% confluent (Day -2) they were allowed to grow for an
additional two days (Day 0). On Day 0, differentiation was induced by treating
cells with culture media supplemented with 0.1µM insulin, 1µM dexamethasone,
and 0.5mM 3-isobutyl-1-methylxanthine (IBMX). After 2 days (Day 2), cells were
treated with culture media supplemented with 0.1µM insulin until Day 8. Media
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was refreshed every two days. To avoid cell detachment from the plate during
differentiation, cells were not washed with PBS during media changes.
2.18.4 Primary Adipocyte Isolation and Differentiation
White adipose tissue was excised from 8-week old CD47 deficient and
wildtype littermate controls, minced, and digested in Ca2+/Mg2+-free HBSS
supplemented with 0.1% collagenase type II (Catalog No. C6885, Sigma, St.
Louis, MO, USA) for 45 minutes in a 37°C shaking water bath. After digestion,
cells were centrifuged at 700 x g for 10 minutes at 4° and the supernatant
including the adipocyte layer was removed. The pellet was digested a second
time with collagenase type II digestion buffer and incubated for 10 additional
minutes in a 37°C shaking water bath. Cells were then filtered through a 100μm
cell strainer and centrifuged again at 400 x g for 5 minutes at 4°. Cells were
suspended in culture media Dulbecco’s Modified Eagle Medium (DMEM, Gibco,
Carlsbad, CA, USA) supplemented with 10% FBS and 1% penicillinstreptomycin. Cell viability was determined with trypan blue staining (>85% cell
viability) and were seeded for various experiments.
For primary white adipocyte differentiation, the following protocol was
used. Once cells were 100% confluent (day -2), they were allowed to continue
growing for an additional 2 days (day 0) in culture media. On day 0,
differentiation was induced by treating the cells with culture media supplemented
with 1.7µM insulin, 0.5mM 3-isobutyl-1-methylxanthine (IBMX), and 1µM
dexamethasone (induction media; all reagents obtained from Sigma, St. Louis,
MO, USA) for three days. On day 3, cells were returned to culture media
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supplemented with 1.7µM insulin (differentiation media) for the remaining
duration of differentiation until day 8. Differentiation media was refreshed every
two days. During media changes, cells were not washed with PBS to avoid cell
detachment from the plate during differentiation.
2.19 Cellular-level ROS Quantification
HepG2 cells and primary hepatocytes were preloaded with 50µM
H2DCFDA and/or IgG Control or anti-human CD47 antibody clone B6H12
(2µg/mL; R&D Systems, Minneapolis, MN, USA) where indicated for thirty
minutes at 37°C. TSP1 was generated through construction plasmids and
purification of GST-fused proteins. After loading, cells were washed 2x with PBS
then treated with palmitate (200µM), purified GST-fused TSP1 (2µg/mL), or GST
as control (2µg/mL) for 6 hours at 37°C. After treatment, DCF fluorescence was
measured with a fluorescent microplate reader (BioTek Synergy H1 Hybrid
Reader, Winooski, VT, USA) at 485nm excitation and 528nm emission. In vitro
experiments were triplicated and results are expressed as relative fluorescence
units (RFU) normalized by cellular protein/well. Total protein concentrations were
measured using BCA assay (Pierce, Waltham, MA, USA).
2.20 Cell Culture Oil Red O Staining
Primary adipocytes were fixed with 4% paraformaldehyde for 15 minutes
at RT. Cells were then washed with PBS for 5 minutes, immediately followed by
a 5 minute wash with freshly prepared 60% isopropanol in water. Working Oil
Red O solution was prepared by mixing 3 volumes of 0.5% Oil Red O in 100%
isopropanol with 2 volumes distilled water and filtering through Whatman 4 filter
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paper. Cells were stained with filtered Oil Red O for 30 minutes and
subsequently washed an additional 4 times with water. Images were acquired
with a Nikon Eclipse 55i microscope. To quantify lipid accumulation, Oil Red O
was extracted by carefully washing cells with 100% isopropanol. Extracted Oil
Red O samples were loaded in triplicate into a clear, flat-bottom 96-well plate and
absorbance was read at 500nm with a microplate reader. Absorbance values
were normalized to protein content per well determined by BCA assay and
presented as fold change over control.
2.21 In Vitro Lipolysis Assay
Lipolysis in fully differentiated 3T3-L1 adipocytes was determined by
measuring free glycerol released into the media. After 8 days of differentiation,
3T3-L1 cells were serum starved for 1 hour and pretreated with either IgG control
or a CD47 functional blocking antibody clone B6H12 (2µg/mL; R&D Systems,
Minneapolis, MN, USA) for 30 minutes prior to treatment. Cells were then treated
with or without c-CPT-cGMP (200µM; Sigma, St. Louis, MO, USA) or
isoproterenol (positive control; 10µM; Sigma, St. Louis, MO, USA). After three
hours, media was collected and glycerol release was measured and normalized
to cellular protein content. Free glycerol levels were determined with Free
Glycerol Reagent and appropriate standards (Sigma, St. Louis, MO, USA).
2.22 Seahorse Assays
To examine differences in mitochondrial function between WT and CD47
deficient primary adipocytes, the XF Mitochondrial Stress Test by Seahorse
Bioscience (Agilent Technologies, Santa Clara, CA, USA) was completed. The
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protocol provided by Seahorse Biosciences used for this assay can be found in
Figure 2.1. On day 8 of differentiation, cells were seeded in an XF96 Seahorse
cell culture plate (Agilent Technologies, Santa Clara, CA, USA) five hours prior to
the assay at a density of 1x104 cells/well (n=7 wells/group). Over the course of
the assay, cells were treated with three different compounds and the oxygen
consumption rate (OCR) was measured before and after each treatment. First,
cells were treated with oligomycin (1µM), which blunts ATP synthesis by blocking
ATP

synthase.

Second,

cells

were

treated

with

carbonyl

cyanide-4-

(trifluoromethoxy) phenylhydrazone (FCCP, 2µM) which uncouples the electron
transport chain and induces high oxygen consumption and energy expenditure
without generating ATP. Finally, cells were treated with a combination of
rotenone (complex I Inhibitor) and antimycin A (complex III inhibitor) (both 1µM).
This combination inhibits all mitochondrial respiration and allows the nonmitochondrial respiration of the cell to be measured. Analysis of data was
completed with XFe Wave Software (Agilent Technologies, Santa Clara, CA,
USA). All values were normalized to cellular protein levels which were
determined by BCA Assay (Pierce, Waltham, MA, USA) following the
manufacturer’s protocol.
2.23 Assessment of Isolated Mitochondria Bioenergetics
Brown adipose tissue mitochondria were isolated using differential
centrifugation with some modifications to the previously described methods (253,
254). Briefly, 500-800mg adipose tissues were excised, minced with a blade, and
placed in isolation buffer with EGTA (215mM mannitol, 75mM sucrose, 0.1%
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BSA, 20mM HEPES, 1mM EGTA, pH adjusted to 7.2 with KOH). Tissues were
mechanically homogenized at 300rpm in 4mL ice cold isolation buffer with EGTA.
The homogenate was centrifuged twice at 1300 x g for 3 min in a 2mL centrifuge
tube at 4°C. Each supernatant fraction was collected in separate tubes and
topped off with isolation buffer with EGTA and finally centrifuged at 13,000 x g for
10min. The mitochondrial pellet was then suspended in 1mL isolation buffer
without EGTA and centrifuged for 10min at 10,000 x g. Finally, the mitochondrial
pellet was resuspended in 30-50µL isolation buffer without EGTA and stored on
ice until the time of assay. The protein concentration was determined using the
BCA assay kit (Pierce, Waltham, MA, USA) following the manufacturer’s
protocol.
Mitochondrial respiration was assessed using a Clark-type oxygen
electrode (Hansatech Instruments, Norfolk, UK), in a sealed, thermostatically
controlled (37°C), and continuously stirred chamber as described previously
(253, 255). Mitochondria were added to the chamber to yield a final protein
concentration of 50µg/mL respiration buffer (215mM mannitol, 75mM sucrose,
2mM MgCl2, 2.5mM inorganic phosphates, 0.1% BSA, 20mM HEPES, pH
adjusted to 7.2). State II respiration was initiated by the addition of oxidative
substrates, pyruvate and malate (5mM and 2.5mM, respectively). State III
respiration was initiated by the addition of 120nmol ADP followed by the addition
of oligomycin (1µM) to induce state IV respiration. UCP-mediated proton
conductance was measured as increased free fatty acid (60µM linoleic acid)
induced respiration (253, 255), followed by recoupling of the mitochondria by
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sequestration of FFA with the addition of BSA to a final concentration of 3%.
Finally, mitochondria were treated with FCCP to allow for quantification of
complex I driven, maximal electron transport.
2.24 Preparation of Purified TSP1
The TSP1 encoding gene was amplified by ultra-based PCR using
pGEM2-htsp1 as a template and subcloned into expression plasmid vector
pGEX-4T-3 after digestion by the restricted endonucleases xho1, Klenow, and
Sal1. The expression plasmids were inserted into competent DH5α cells and
expression of proteins were evaluated by 8% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). The GST-TSP1 fusion protein
expression was induced by IPTG in competent BL21(DE3) E. coli and was
purified with a GST column. Endotoxins were removed with a Detoxi-Gel
Endotoxin removing column (Pierce, Waltham, MA, USA) and quantified with the
LAL Chromogenic Endotoxin Quantitation Kit (Pierce, Waltham, MA, USA). The
purified protein was stored in aliquots at −80 °C.
2.25 Preparation of In Vitro Fatty Acid Treatments
To represent physiological conditions, palmitic acid (PA; Sigma, St. Louis,
MO, USA) was conjugated to fatty acid-free BSA prior to all in vitro treatments as
previously described (114). Stock palmitic acid solution in100% ethanol (100mM)
was added to 10% BSA solution in serum-free media and incubated at 37°C for
30 minutes to prepare a 5mM BSA-PA solution. As indicated, BSA controls were
treated with stocks of 10% w/w BSA plus equal volumes of 100% ethanol added
to match concentration of palmitate treatment.

62

2.26 Statistical Analysis
Data are expressed as the mean value ± standard error (SE). Student’s ttests were used for measuring differences between two groups. Data from 3 or
more groups with one experimental variable were analyzed by one-way ANOVA
(e.g. cell culture treatments). Data were analyzed by a two-way ANOVA when 2
groups with 2 or more variable were present (diet and genotype) and Bonferroni
ad hoc tests were used when appropriate to measure significance between all
groups, unless otherwise indicated. A p value of <0.05 was considered
statistically significant. All statistical analyses were completed utilizing GraphPad
Prism.
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Table 2.1 Primer sequences used in studies
Gene

Forward (5’-3’)

Reverse (5’-3’)

Accession
Number

18s

AGTCGGCATCGTTTATGGTC

CGAAAGCATTTGCCAAGAAT

NR_002170

ACO

GACAGAGGTCCACGAATCTTAC

GGCTACTACTGCACCTACAAC

NM_015729

ATPSyn

TGTGTCCCGGGCAAGAAAGATACA

AAGGCTTGTTCTGGGAGATGGTCA

NM_016774

CCR2

AGAGAGCTGCAGCAAAAAGG

GGAAAGAGGCAGTTGCAAAG

NM_009915

CD11c

CTGGATAGCCTTTCTTCTGCTG

GCACACTGTGTCCGAACTC

NM_021334

CD36

ACTGGTGGATGGTTTCCTAGCCTT

TTTCTCGCCAACTCCCAGGTACAA

NM_001159555

CD47

AGAATGCTTCTGGACTTGGCCTCA

TCACATGCCATGATGCAGAGACAC

HQ585874

Col IαI

TTCTCCTGGCAAAGACGGACTCAA

AGGAAGCTGAAGTCATAACCGCCA

NM_007742

Col III

TCCTAACCAAGGCTGCAAGATGGA

TCCTAACCAAGGCTGCAAGATGGA

NM_009930

Col IV

AGGGTTCCCAGGTTCTAA

GCCCAACGTCACCTTTAT

NM_009932

COXI

ACTTGCAACCCTACACGGAGGTAA

TCGTGAAGCACGATGTCAAGGGAT

NC_005089.1

COXIII

TCAGCCCTCCTTCTAACATCAGGT

AATAGGAGTGTGGTGGCCTTGGTA

NC_005089.1

CPT1a

CTCTATGTGGTGTCCAAG

CACAGGACACATAGTCAG

NM_013495.2

CPT1b

ACCTGAGCTGTGCTGAATAAA

ACAGGAGACGGACACAGATA

NM_009948

F4/80

AGTCGGCATCGTTTATGGTC

CGAAAGCATTTGCCAAGAAT

X93328

FATP1

GGAGTCTGGAATGCTGAGAAG

ATCAGAACAGAGAGGCCAAAG

NM_011977

FATP2

GACCCAGACAGAGAAGAA

TCCACCGGAAAGTATCTC

AF072757

FATP5

CTGCGGTACTTGTGTAAC

TGGATCCGTAGAATTCCC

AF072760

G6P

CCCAGGTTGAGTTGATCTTC

GACTTCTTGTGTGTCTGTCC

NM_008061.4

MCP1

CAGCCAGATGCAGTTAACGC

GCCTACTCATTGGGATCATCTTG

NM_011333

mtDNA

CCGCAAGGGAAAGATGAAAGA

TCGTTTGGTTTCGGGGTTTC

AP013030.1

MTTP

TCTGCCTATACTGGCTAC

CCGATGTACTGGAAGATG

XM_017319475

nDNA

GCCAGCCTCTCCTGATTTTAGTGT

GGGAACACAAAAGACCTCTTCTGG

NR_003279.1

Pepck

ACACCATCTTCACCAACG

GTCTCCACTCCTTGTTCTTC

NM_011044.2

PGC1α

CTGCATGAGTGTGTGCTGTG

CAAATATGTTCGCAGGCTCA

NM_008904

PPARα

CTCCTTGCTGCCAATCAA

CAAACATAGGACCAGCTCTC

NM_011144

PPARγ

TGCTGTTATGGGTGAAACTCTG

CTGTGTCAACCATGGTAATTTCTT

NM_011146

SREBP1c

GGAGCCATGGATTGCACATT

ACAAGGGTGCAGGTGTCACC

XM_006532717

TNFα

AGCCGATGGGTTGTACCT

TGAGTTGGTCCCCCTTCT

NM_013693

UCP1

TACCAAGCTGTGCGATGT

AAGCCCAATGATGTTCAGT

NM_009463

UCP3

ACCTGGACTGCATGGTAAGG

GAGAGCAGGAGGAAGTGTGG

NM_009464

7714

CAAGCATAAATGAACAGTTGCAG

7297

CGTTGGCTACCCGTGATATT

13700

CACCTTACAGCACTCCCACA
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Figure 2.1 Seahorse Biosciences Mitochondrial Stress Test Protocol
Detailed protocol for the XF Mito Stress Test as previously described (88).
Fundamental parameters of mitochondrial function, including basal respiration,
ATP production, proton leak, maximal respiration, and spare respiratory capacity,
can be determined by measuring oxygen consumption rates (OCR) before and
after various drug treatments. Oligomycin inhibits ATP Synthase (Complex V).
FCCP uncouples the electron transport chain (ETC) by increasing hydrogen ion
translocation across the inner mitochondrial membrane. Combinational treatment
with rotenone/antimycin A target and disrupt the function of complexes I and III in
the ETC.
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Section 3: SPECIFIC AIM 1
Portions of this section are reprinted from Macmillan Publishers Ltd: Scientific
Reports (156), © 2015. Published under a CC-BY 4.0 Creative Commons license
http://creativecommons.org/licenses/by/4.0
3.1 Summary
CD47 is a transmembrane protein with several functions including selfrecognition, immune cell communication, and cell signaling. Although it has been
extensively studied in cancer and ischemia, CD47 function in obesity has never
been explored. In this study, we utilized CD47 deficient mice in a high-fat diet
induced obesity model to study for the first time whether CD47 plays a role in the
development

of obesity and

metabolic

complications.

Age-matched,

male CD47 deficient and C57BL6/J wild type (WT) control mice were fed with
either low fat (LF) or high fat (HF) diets for 16 weeks. Interestingly, we found
that CD47 deficient mice were protected from HF diet-induced obesity displaying
decreased weight gain and reduced adiposity. This led to decreased
MCP1/CCR2 dependent macrophage infiltration into adipose tissue and reduced
inflammation, resulting in improved glucose tolerance and insulin sensitivity. In
addition, CD47 deficiency stimulated the expression of UCP1 and carnitine
palmitoyltransferase 1b (CPT1b) levels in brown adipose tissue, leading to
increased lipid utilization and heat production. Additional studies suggest
increased lipid mobilization in white adipose tissue may provide energy substrate
for enhanced brown adipose tissue metabolic function in CD47 deficient mice,
ultimately contributing to the increased energy utilization and reduced adiposity
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observed in these mice. Taken together, these data reveal a novel role
for CD47 in the development of obesity and its related metabolic complications.
3.2 Introduction
Obesity and its-associated insulin resistance is rampant within the United
States and other developed nations. Previous studies from our lab and others
suggest that thrombospondin 1 (TSP1) plays an important role in obesityassociated chronic inflammation and insulin resistance (IR) (100, 128, 144, 268).
We demonstrated that TSP1 deficiency did not affect the development of high-fat
diet induced adiposity. However, TSP1 deficiency reduced macrophage
accumulation in adipose tissue and protected against obesity related
inflammation and insulin resistance (144). These data suggest that TSP1 plays
an important role in regulating macrophage function and mediating obesityinduced inflammation and insulin resistance. However, the mechanisms of the
proinflammatory effect elicited by TSP1 under obese conditions remain to be
determined.
TSP1, a 420–450 kDa homotrimer, is a multifunctional matricellular protein
composed of several domains that can interact with different cell surface
receptors (25, 33, 38, 75, 78, 84, 113, 138, 169, 178, 258, 276). TSP1 is a highly
potent ligand for CD47, a trans-membrane glycoprotein cell receptor that belongs
to the immunoglobulin superfamily (160). CD47 is expressed in various tissues
and cell types throughout the body, ranging from microglia to endothelial cells
(28, 193). Wide expression suggests that CD47 is active or necessary in several
different cellular pathways including immunity and self-recognition, inflammation,
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cellular adhesion, stress response, cell survival, and vascular function (16, 103,
106, 109, 219). It has been shown that the TSP1-CD47 interaction inhibits
NO/cGMP/PKG signaling in vascular smooth muscle cells and plays a role in
vasoconstriction and inflammation (106, 107, 207, 297). However, it is unknown
whether the proinflammatory effect elicited by TSP1 under obese conditions is
mediated by CD47.
In the current study, we determined whether TSP1 promotes obesityassociated inflammation and insulin resistance through interaction with its
receptor-CD47. We utilized CD47 deficient and WT mice in a diet-induced
obesity paradigm. CD47 deficient mice challenged with a HF diet had several
protective phenotypes as previously observed in TSP1 deficient mice including
decreased obesity-associated inflammation and improved glucose tolerance and
insulin sensitivity (144). However, significant reductions in body weight were
observed in CD47 deficient mice and not HF-fed TSP1 deficient mice in the
previous study (144). Current studies have shown that CD47 deficiency protected
mice from HF diet induced obesity; while TSP1 deficiency had no effect on dietinduced obesity after 16 weeks of HF feeding (144). Moreover, CD47 deficiency
resulted in tissue-specific effects on metabolic organs in vivo. First, CD47
deficient mice exhibited increased energy expenditure, heat production, and core
body temperature partially relating to brown adipose tissue and/or skeletal
muscle functional changes. These mice also displayed increased white adipose
tissue lipolysis which could fuel enhanced brown adipose tissue metabolic
activity and contribute to a leaner whole body phenotype. Together, data from
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this study revealed a novel role for CD47 in regulation of energy homeostasis
and the development of obesity, suggesting that CD47 may serve as a potential
therapeutic target to combat obesity and metabolic complications.
3.3 Results
3.3.1 CD47 deficiency protects mice from diet-induced obesity.
To assess the metabolic role of CD47 in mice, CD47 deficient mice and
WT controls were challenged with either a low fat (LF, 10% kcal from fat) or high
fat (HF, 60% kcal from fat) diet for 16 weeks. Under LF diet conditions, although
CD47 deficient mice had a trend of decrease in body weight as compared to WT
mice, no significant changes in body weight gain were observed throughout the
study (Figure 3.1 A, B). When challenged with HF diet, CD47 deficient mice
exhibited significantly reduced body weight starting from 7 weeks' feeding until
the end of the study. These mice gained less weight than HF-fed WT mice
(Figure 3.1 A, B; P<0.05). At the end of study, body composition was determined
in mice by using EchoMRI. There was significantly reduced fat mass in HF-fed
CD47 deficient mice as compared to HF-fed WT mice (Figure 3.1 C; P<0.05),
which was in agreement with the absolute weight of different adipose tissue
depots (Figure 3.1 E; P<0.05 for all white adipose tissue depots). Lean mass was
comparable in HF-fed CD47 deficient mice and WT mice (Figure 3.1 D).
Consistent with the decreased adiposity, HF-fed CD47 deficient mice had
reduced leptin levels (ng/ml, WT HF: 14.4 ± 4.9 vs. CD47-/- HF: 6.8 ± 1.1,
P<0.05). Moreover, plasma total cholesterol (TC) and free fatty acid (FFA) levels
were significantly reduced in HF-fed CD47 deficient mice (TC (mg/dl), WT HF:
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115.1 ± 7.3 vs. CD47-/- HF: 80.0 ± 7.9, P<0.01; FFA (mEq/L), WT HF: 0.34 ±
0.01 vs. CD47-/- HF: 0.28 ± 0.02, P<0.05). Daily cumulative food consumption
was measured and there was no significant difference between either genotype
or diet type (Figure 3.6 A). Together, these data suggests that CD47 deficiency
protects mice from diet-induced obesity.
3.3.2 CD47 deficient mice on HF diet showed reduced systemic and
adipose tissue inflammation.
Systemic and adipose tissue inflammation were determined in four groups
of mice. As shown in Figure 3.2 A and B, HF-fed CD47 deficient mice had a
significant reduction in plasma TNFα (P<0.01) and IL-6 (P<0.05) levels compared
with HF controls. In addition to the reduced plasma proinflammatory cytokines,
plasma anti-inflammatory cytokine-IL-10 levels were significantly increased in
HF-fed CD47 deficient mice as compared to HF-fed WT mice or to LF-fed CD47
deficient mice (Figure 3.2 C; P<0.05), suggesting that the interaction between
diet composition and genotype contributes to the IL-10 secretion.
In addition to systemic inflammation, adipose tissue inflammation status
was determined. Visceral adipose tissue has been suggested to be the primary
source of cytokine and adipokine release within obesity-associated inflammation
(275). Moreover, increased accumulation of adipose tissue macrophages is a
significant contributor to obesity-induced chronic inflammation (130, 281, 294).
Therefore macrophage infiltration into adipose tissue was determined by
immunohistochemical staining for the macrophage marker F4/80. As shown
in Figure 3.3 A, HF-fed WT controls had robust positive staining of F4/80 and
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crown-like structures, yet HF-fed CD47 deficient mice had minimal positive
staining, suggesting a decreased presence of macrophages. We confirmed this
staining result with qPCR and demonstrated that HF-fed WT controls had a
significant increase in F4/80 expression in adipose tissue, which was reduced in
HF-fed CD47 deficient mice (Figure 3.3 B; P<0.01). Moreover, CD11c and TNF-α
levels were increased in adipose tissue from HF-fed WT mice compared with LF
controls, but decreased in HF-fed CD47deficient mice (Figure 3.3 B; P<0.01,
P<0.05, respectively). Together, these data indicate that CD47 deficient mice had
reduced macrophage infiltration into adipose tissue and decreased systemic and
adipose tissue inflammation in response to HF diet compared with controls.
To determine the mechanism of reduced macrophage infiltration in
adipose tissue from HF-fed CD47 deficient mice, we examined MCP1 and CCR2
levels. MCP1, an inflammatory chemokine responsible for monocyte migration,
and its dominant receptor CCR2 are suggested to be responsible for a significant
amount of monocyte infiltration into inflamed adipose tissue (281). We found that
HF-fed CD47 deficient mice demonstrated a reduction in MCP1 and CCR2 levels
in adipose tissue (Figure 3.3 B; P<0.05), which might be due to the reduced
adiposity in these mice. In addition, this result could explain the significant
decrease in macrophage infiltration in adipose tissue from CD47 deficient mice,
which was supported by an in vitro migration studies using isolated macrophages
from HF fed WT and CD47 deficient mice. We found that WT macrophages had
increased MCP1 stimulated migration; while macrophages from CD47 deficient
mice showed reduced migration basally (P<0.05) and in response to MCP1
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(Figure 3.3 C; P<0.01). Together, these data suggest that CD47 regulates dietinduced adipose tissue macrophage infiltration and inflammation through a
MCP1/CCR2 dependent pathway.
3.3.3 CD47 deficient mice on HF diet showed improved whole body
glucose homeostasis.
The liver morphology was determined in the current study. We found that
CD47 deficiency protected mice from hepatosteatosis when fed with HF diet,
which was demonstrated by reduced liver weight, Oil Red O staining in liver
sections and liver triglyceride levels (Figure 3.4 A, C; P<0.05). To determine
whole body glucose homeostasis, we performed glucose tolerance and insulin
sensitivity tests in WT and CD47 deficient mice. As shown in Figure 3.5, glucose
tolerance and insulin sensitivity were significantly improved in HF-fed CD47
deficient mice as compared to HF-fed WT mice (P<0.05), suggesting that CD47
deficiency protects mice from diet-induced glucose intolerance and insulin
resistance.
3.3.4 Energy metabolism in WT or CD47 deficient mice under either
LF or HF feeding conditions
We have shown that CD47 deficiency protects mice from diet-induced
obesity. To further elucidate its mechanism, we examined energy balance in both
WT and CD47 deficient mice. CD47 deficient mice displayed elevated energy
expenditure (normalized to total body mass), heat production, core body
temperature, and total activity compared to WT mice in either light or dark cycle
(Figure 3.6 B–E). Together, these data suggest that the protection against HF
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diet induced weight gain and fat gain in CD47 deficient mice might be due to
increased energy utilization.
3.3.5 Metabolic gene expression in skeletal muscle from LF or HF fed
WT and CD47 deficient mice
To further determine the mechanism of increased energy utilization in HFfed CD47 deficient mice, we analyzed the expression of multiple genes in
skeletal muscle that relate to mitochondria function and fuel utilization. The
rationale for this analysis was based on the previous report showing that skeletal
muscle from CD47 deficient mice had greater number of mitochondria and
improved function (74), which suggested a possible relationship between skeletal
muscle function and the metabolic phenotype observed in the current study.
Therefore, mitochondria DNA copy number and expression of a series genes
relating to mitochondria oxidative function and fatty acid catabolism were
analyzed. Consistent with previous reports (74), the results showed that
mitochondria DNA copy number was significantly increased in CD47 deficient
mice compared to WT mice under both LF and HF feeding conditions (Figure 3.7
A; P<0.05). However, expression levels of genes related to mitochondria
oxidative function and fatty acid catabolism were comparable in CD47 deficient
mice compared to WT mice under both LF and HF feeding conditions (Figure 3.7
B), suggesting that skeletal muscle functional changes may not be a major
contributor to the increased energy utilization phenotype in HF-fed CD47
deficient mice.
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3.3.6 Morphology and metabolic gene expression in brown adipose
tissue from LF or HF fed WT and CD47 deficient mice
Recently, brown adipose tissue (BAT) has emerged as an important
player in energy metabolism (32). However, whether CD47 regulates BAT
function and contributes to diet-induced obesity is unknown. First, we found that
diet-induced obesity significantly up-regulated CD47 protein levels in BAT in wild
type mice (Figure 3.8 A; P<0.05). Although interscapular BAT weight was not
different between WT and CD47 deficient mice under either LF or HF feeding
conditions (Figure 3.1 E), histology showed a decrease in intracellular lipid
droplet size in BAT of HF-fed CD47 deficient mice compared to HF-fed WT mice,
reflected by a decrease in relative lipid area (Figure 3.8 B, C; P<0.01). Moreover,
we analyzed mitochondria DNA copy number and a series of genes relating to
mitochondria oxidative function and fatty acid catabolism. As shown in Figure 3.8
D, mitochondria DNA copy number in BAT was increased in HF-fed CD47
deficient mice compared to HF WT mice, although not significantly. This
suggests that CD47 may regulate mitochondria biogenesis in BAT. In addition,
mRNA levels of UCP1 and carnitine palmitoyltransferase 1B (CPT1b) in BAT
were significantly increased in HF-fed CD47 deficient mice (Figure 3.8 E; P<0.05,
P<0.01, respectively).
BAT expends a large amount of energy through mitochondria β-oxidation
and by uncoupling of the mitochondria proton gradient from ATP production. This
uncoupling results in heat production or thermogenesis, accomplished by UCP1
located in the inner mitochondria membrane (31, 213). CPT1b, located on the
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outer mitochondrial membrane, is the first and rate-limiting step for fatty acid
transport into the mitochondria for utilization (233). Therefore, these data suggest
that CD47 deficiency-mediated CPT1b expression in BAT may lead to increased
fatty acid uptake in mitochondria and subsequent activation of UCP1, resulting in
increased uncoupling and heat production (Figure 3.6 C, D).
3.3.7 cGMP/PKG signaling in WT and CD47 deficient mice under
either LF or HF feeding conditions
Studies have shown that CD47 activation via TSP1 can disrupt
NO/cGMP/PKG signaling in vascular cells (93, 109, 214). Therefore, we
determined whether cGMP/PKG signaling in BAT or skeletal muscle was altered
in CD47 deficient mice under either LF or HF feeding conditions. As shown
in Figure 3.9 A, under LF feeding conditions, cGMP levels in BAT were higher in
CD47 deficient mice compared to WT mice (P<0.05). HF diet feeding significantly
reduced BAT cGMP levels in both WT and CD47 deficient mice compared to
their LF controls (P<0.05); however, levels in HF-fed CD47 deficient mice were
comparable to WT mice fed a LF diet. For PKG-I protein levels in BAT, under LF
feeding conditions, no difference was found between WT and CD47 deficient
mice. However, under HF feeding conditions, BAT PKG-I protein levels were
significantly increased in CD47 deficient mice compared to WT mice (Figure 3.9
B; P<0.01).
In addition to brown fat, cGMP/PKG signaling in skeletal muscle was
analyzed. We found that cGMP levels or PKG-I protein levels were higher in LFfed CD47 deficient mice compared to LF-fed WT mice (Figure 3.9 C, D; P<0.01).
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However, under HF feeding conditions, there was no difference in cGMP or PKGI levels between WT and CD47 deficient mice. Together, these data suggest that
cGMP/PKG signaling was differentially regulated by CD47 in BAT and skeletal
muscle.
3.3.8 Characterization of white adipose tissue depots in CD47
deficient mice challenged with HF diet
In the current studies, we have shown that CD47 deficient mice are
protected against the development of diet-induced obesity (Figure 3.1). To further
understand the role of CD47 in white adipose tissue expansion under HF
conditions, adipocyte size was measured in both subcutaneous adipose tissue
(SAT) depots and epididymal adipose tissue (EAT). Similar to the phenotype
observed in BAT (Figure 3.8 B), CD47 deficiency was associated with a
significant reduction in lipid droplet size under LF and HF conditions in SAT
(Figure 3.10 A; P<0.05 between LF groups, P<0.01 between HF groups) and
EAT (Figure 3.10 B; P<0.05 between LF and HF groups). This phenotype
suggests a unique effect of CD47 on lipid storage independent of diet.
3.3.9 White adipocyte function in vitro
Several mechanisms regulate intracellular lipid levels within adipocytes,
including the rates of lipogenesis/lipid storage, fatty acid oxidation, and liberation
of FFAs from intracellular lipid droplets as a fuel source for metabolically active
peripheral tissues. In order to determine the mechanism(s) contributing to a
significant reduction in adipocyte size in WAT, in vitro studies utilizing primary
adipocytes and the immortalized preadipocyte 3T3-L1 cells were completed.
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First, stromal vascular fraction was isolated from both 8-week old CD47 deficient
and

age-matched

control

white

adipose

tissue

depots,

cultured,

and

differentiated into mature adipocytes as previously described in Section 2.18.4.
To determine whether CD47 deficiency impairs adipogenesis and lipid storage in
white adipocytes, CD47 deficient and control primary adipocytes were stained
with Oil Red O on day 8 of differentiation to assess lipid accumulation. Our
studies demonstrated no significant difference in lipid accumulation as indicated
by Oil Red O staining of intracellular lipid (Figure 3.11 A, B). These data suggest
impaired adipogenesis and lipid storage is not the cause for reduced adipocyte
size in vivo.
In addition, mitochondrial function was assessed in CD47 deficient and
control white adipocytes on day 8 of differentiation using the Seahorse XF96 Flux
Analyzer (Agilent Technologies, Santa Clara, CA, USA). Basal respiration, ATP
production, non-mitochondrial respiration, and maximal respiratory capacity were
determined by measuring oxygen consumption rates (OCR) with the protocol
detailed in Figure 2.1. CD47 deficient and control white adipocytes exhibited no
significant difference in any mitochondrial function parameters (Figure 3.11.D, E),
suggesting increased fatty acid-dependent metabolic activity is not contributing to
reduce adipocyte size. Because we saw no differences in lipogenesis or
mitochondrial respiration between genotypes in vitro, we conclude the smaller
adipocyte phenotype in vivo (Figure 3.10) may be a result of crosstalk with other
metabolic tissues and enhanced global energy requirements.
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3.3.10 Regulation of lipid turnover by CD47
It has been previously determined that cGMP/PKG signaling regulates
lipolysis by activating lipases critical for the hydrolysis of triglycerides in lipid
droplets (185). In addition, it has been well established that activation of CD47
suppresses cGMP/PKG signaling in a number of tissues (93, 109, 214). As a
potential mechanism for reduced white adipocyte size, the role of CD47 in white
adipocyte lipolysis was examined in vivo, ex vivo, and in vitro. After a six hour
fast, eight-week old CD47 deficient and wildtype littermate control mice were
intraperitoneally injected with vehicle or CL 316,243 (1mg/kg BW), a β-adrenergic
agonist, to induce lipolysis. Independent of treatment, CD47 deficiency
significantly increased plasma levels of free glycerol, a common indicator of
lipolysis (Figure 3.12 A; P<0.05). Ex vivo lipolysis assays determined that lack of
CD47 expression, independent of β-adrenergic stimulation, enhanced glycerol
release from white adipose tissue depots but not from BAT (Figure 3.12 B; EAT:
P<0.05 basally, P<0.01 stimulated; SAT: p=0.06 basally, P<0.001 stimulated).
Further, fully differentiated 3T3-L1 cells were serum starved and
pretreated with or without IgG control or a functional blocking antibody targeting
CD47 for 30 minutes. Cells were then treated with c-CPT-cGMP (200µM), a
cGMP agonist, or isoproterenol (10µM), a non-specific β-agonist, as a positive
control. Our studies show that treatment with cGMP and a CD47 functional
blocking antibody (clone B6H12) significantly increase glycerol levels in the
media, indicative of lipid mobilization, compared with controls (Figure 3.12 C;
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P<0.05). These data suggest that reduced CD47 activity contributes to increased
lipid droplet turnover in white adipose tissue.
3.3.11 FFA-mediated uncoupling of brown adipose tissue
mitochondria
It is well established that FFAs are an efficient fuel source for enhanced
mitochondrial respiration in BAT and directly stimulate uncoupling by interacting
with UCP1 (67). In the current studies we have shown that CD47 deficiency is
associated with increased CPT1b and UCP1 expression in brown adipose tissue
despite HF diet challenge (Figure 3.8). We propose that increased lipid
mobilization in CD47 deficient mice drives enhanced FA oxidation and UCP1mediated uncoupling in BAT. To measure this, mitochondria were isolated from
brown adipose tissue of age-matched CD47 deficient and littermate control mice
and treated with various compounds to examine mitochondrial bioenergetics. It is
clear that mitochondria from WT BAT are uncoupled, which is indicated by the
continuous oxygen consumption despite oligomycin treatment, which should
blunt all ETC-mediated oxygen consumption and ATP generation (Figure 3.13
A). However, mitochondria isolated from CD47 deficient BAT demonstrated a
significant increase in the State IV and FFA-mediated UCP activation (Figure
3.13 B; P<0.05). This indicates that CD47 deficient BAT mitochondria are
adapted to consume more oxygen and generate more heat compared to WT.
3.4 Discussion
CD47 is a transmembrane protein with several functions including selfrecognition, immune cell communication, and cell signaling (28, 193). Although it
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has been extensively studied in cancer and ischemia (165, 238, 241, 286), CD47
function in obesity has never been explored. In this study, we utilized CD47
deficient mice in a high-fat diet induced obesity model to study for the first time
whether CD47 plays a role in diet-induced obesity and its associated metabolic
complications. As previously reported (74), CD47 deficiency was associated with
a leaner phenotype, although not significant, in the LF-fed group through the
duration of the study compared with LF controls; however, body weight gain was
consistent and no improvements in other metabolic parameters were identified
between the two control groups. In our HF-mice, we found that CD47 deficient
mice were protected from diet-induced obesity displaying decreased weight gain
and reduced adiposity despite comparable daily food consumption and no
impairments in intestinal lipid absorption (data not shown). This led to decreased
MCP1/CCR2 dependent macrophage infiltration into adipose tissue and reduced
inflammation, resulting in improved glucose tolerance and insulin sensitivity. In
addition, CD47 deficiency stimulated the expression of UCP1 and CPT1b levels
in brown adipose tissue, leading to increased lipid utilization and heat production
and contributing to increased energy utilization and reduced adiposity in these
mice. To support this, additional studies were completed under basal conditions
that demonstrate CD47 deficiency is associated with enhanced white adipose
tissue lipolysis and increased FFA-dependent mitochondrial respiration in brown
adipose tissue. These data suggest a novel role for CD47 in regulation of
metabolic function, energy homeostasis, and its contribution to the development
of obesity and dyslipidemia.
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CD47 is a receptor for the matricellular protein-thrombospondin 1 (TSP1).
Previous studies from our lab and others suggest that TSP1 plays a role in
obesity-associated chronic inflammation and insulin resistance (100, 128, 144,
268). Both TSP1 and CD47 expression in adipose tissue was up-regulated under
obese conditions (128, 268), suggesting that CD47 may mediate the effects of
TSP1 on diet-induced obesity and obesity-associated complications. By feeding
CD47 deficient mice with the same diet (10% (LF) and 60% fat (HF) diet) for the
same time period (16 weeks) as we did before with TSP1 deficient mice (144),
we found that most of the phenotypes observed in the TSP1 deficient mice
undergoing HF feeding were replicated in CD47 deficient mice including reduced
macrophage infiltration into adipose tissue, reduced inflammation, and improved
glucose tolerance and insulin sensitivity. However, one different phenotype was
observed between CD47 deficient mice and our previous HF-fed TSP1 deficient
mice (144), which was the significant changes in body weight. Current studies
showed that CD47 deficiency protected mice from HF diet induced obesity; while
TSP1 deficiency had no effect on diet-induced obesity after 16 weeks of HF
feeding. This different phenotype suggests that TSP1-CD47 ligation may not be
involved in regulation of energy homeostasis under HF feeding conditions. The
novel CD47 ligands and their interaction on energy balance and the development
of obesity warrant further investigation.
It has been shown that CD47 activation via TSP1 can disrupt the NOcGMP pathway and that decreased NO/cGMP signaling contributes to vascular
inflammation as well as adipose tissue inflammation, resulting in insulin
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resistance (93, 214). In agreement with these observations, HF-fed CD47
deficient mice showed decreased levels of circulating proinflammatory cytokines
as well as reduced inflammation in adipose tissue. They also had improved
glucose tolerance and insulin sensitivity. Moreover, with reduced adiposity in HFfed CD47 deficient mice, these mice exhibited reduced expression of MCP1 and
CCR2 in adipose tissue. This was associated with reduced macrophage
infiltration into adipose tissue in HF-fed CD47 deficient mice, which may be
secondary to reduced adiposity. Further in vitro analysis demonstrated that CD47
deficient macrophages had significantly decreased migration compared to WT
cells upon stimulation with MCP1. The importance of MCP1 and CCR2 in
adipose tissue macrophage recruitment and their contribution to insulin
resistance has been demonstrated by numerous studies (89, 116, 117, 191, 256,
280). Thus, data from our study suggest that the effect of CD47 on macrophage
infiltration into adipose tissue and the development of chronic inflammation under
obese conditions is MCP1/CCR2 dependent.
In this study, we found that CD47 deficiency protected mice from HF diet
induced obesity, which was associated with increased energy utilization. To
determine the mechanisms of increased metabolic rate in HF-fed CD47 deficient
mice, we analyzed skeletal muscle function since a previous report showed that
skeletal muscle from CD47 deficient mice had greater number of mitochondria
and improved skeletal muscle function (74). Although we saw increased
mitochondrial number in skeletal muscle and increased locomotor activity in HFfed CD47 deficient mice compared to HF-fed WT mice, the expression of genes
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relating to mitochondria oxidative function or fatty acid catabolism in skeletal
muscle were comparable between WT and CD47 deficient mice (Figure 3.7).
These data suggest that enhanced skeletal muscle function may not be driving
the increased energy expenditure phenotype in HF-fed CD47 deficient mice.
The contribution of brown adipose tissue function to the increased
metabolic rate in HF-fed CD47 deficient mice was also analyzed. The rationale
for such studies is based on previous reports showing that increased cGMP/PKG
signaling pathway stimulates brown adipocyte differentiation (90), promotes
healthy expansion and browning of white adipose tissue (171), stimulates white
adipose tissue lipolysis and cold induced brown fat thermogenesis (185). BAT is
highly vascularized, highly innervated by the sympathetic nervous system, and is
densely packed with mitochondria. BAT expends a large amount of energy
through mitochondria β-oxidation and by uncoupling of the mitochondria proton
gradient from ATP production. This uncoupling results in heat production or
thermogenesis, accomplished by UCP1 located in the inner mitochondria
membrane (31, 213).
It has been well-established that obesity reduces BAT-mediated energy
expenditure and UCP1-driven thermogenesis (197, 215, 237). Although WT and
CD47 deficient mice exhibited comparable brown fat mass and mitochondrial
DNA content, loss of CD47 significantly increased UCP1 mRNA expression in
brown fat under HF feeding conditions. Consistently, we found that core body
temperature was elevated in HF-fed CD47 deficient mice, indicating increased
thermogenesis. We demonstrated that cGMP and/or PKG signaling was up-
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regulated in brown fat from CD47 deficient mice, which could augment healthy
BAT function despite HF diet challenge. Moreover, the lipid accumulation in
brown fat was significantly reduced in HF-fed CD47 deficient mice. UCP1
expression was not found in white fat from either WT or CD47 deficient mice
under either LF or HF feeding conditions (data not shown), suggesting there was
no browning of white fat and a BAT-specific effect of CD47 deficiency.
Because of the global effect of CD47 deficiency on lipid accumulation,
white adipose tissue function was also examined. To elucidate a mechanism for
reduced white adipocyte size, in vitro studies were completed that determined
CD47 deficiency does not impair white adipogenesis/lipid storage and does not
enhance white adipocyte mitochondrial function. Moreover, CD47 deficient mice
displayed enhanced white adipose tissue lipolysis which could contribute to
smaller adipocyte and tissue depot size in vivo. Interestingly, CD47 deficient
mice were not dyslipidemic or insulin resistant, suggesting enhanced lipolysis is
not a result of impaired adipose tissue insulin signaling or contributing to poor
cardiovascular health. Rather, enhanced lipid mobilization could be a result of
increased metabolic activity in other metabolic tissues.
It is known that fatty acids are an important fuel for thermogenesis.
Lipolysis releases fatty acids that can be used for mitochondria oxidation and
thermogenesis. We found that carnitine palmitoyltransferase 1b (CPT1b) was upregulated in BAT from HF-fed CD47 deficient mice compared to HF-fed WT mice.
CPT1b, located on the outer mitochondrial membrane, is the first and ratelimiting step for fatty acid transport into the mitochondria for utilization (233).
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Therefore, CD47 deficiency may increase fatty acid translocation into
mitochondria by fatty acid transporter CPT1b and drive the activation of UCP1 in
brown fat and increased heat production. Interestingly, when isolated
mitochondria from CD47 deficient BAT were treated with FFA we saw a robust
uncoupling effect compared with WT BAT mitochondria supporting our proposal
that CD47 deficiency enhances FFA-mediated BAT activation. These findings
indicate that CD47 deficient mice have increased respiratory capacity as well as
induced uncoupling, which ultimately leads to increased consumption of oxygen
and energy. Together, our data suggest that CD47 mediated regulation of white
and brown fat function contributes to the metabolic phenotype observed in the
current study. However, to demonstrate definitively the effect of brown fat cell
derived CD47 on energy metabolism in diet-induced obesity, the tissue specific
CD47 deficient mice are required in future studies.
In summary, for the first time, our studies demonstrate an important role
for CD47 in regulating energy balance and the development of obesity and its
metabolic complications in a tissue-specific manner. CD47 deficiency protects
mice from HF diet-induced obesity through stimulation of energy expenditure and
heat production. In addition, CD47 deficiency reduces obesity-associated
metabolic complications including decreased systemic and adipose tissue
inflammation and hepatosteatosis, and improved glucose tolerance and insulin
sensitivity. The results from this study suggest that CD47 may serve as a
therapeutic target of obesity and its related comorbidities.
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Figure 3.1 Weight-related measures after LF/HF diet challenge
CD47 deficient mice were protected from high fat diet-induced obesity. Eight
week old male CD47 deficient mice and wild type C57BL6 controls were fed with
low fat (LF) or high fat (HF) diet for 16 weeks. Weekly body weight (A) and body
weight gain (B) are shown and were analyzed by two-way repeated measures
ANOVA. Fat (C) and lean mass (D) of mice were measured by EchoMRI.
Absolute weight of white and brown adipose tissue depots (E) were measured
immediately following sacrifice. Data are presented as mean ± SE (n=5-7
mice/group), *P<0.05, **P<0.01. EAT: epididymal adipose tissue; MAT:
mesenteric adipose tissue; PAT: perirenal adipose tissue; SAT: subcutaneous
adipose tissue; BAT: brown adipose tissue.
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Figure 3.2 Obesity-associated systemic inflammation
HF-fed CD47 deficient mice displayed reduced systemic inflammation compared
to HF-fed wild type controls. Plasma TNFα (A), IL-6 (B), and IL-10 (C) levels
were measured by ELISA as described in Methods. Data are presented as mean
± SE (n=5-7 mice/group), *P<0.05 and **P<0.01.
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Figure 3.3 Adipose tissue inflammation and macrophage infiltration
HF-fed CD47 deficient mice had decreased adipose tissue macrophage
infiltration and inflammation. Macrophage accumulation in epididymal adipose
tissue (A) was determined by anti-F4/80 staining. The positive staining showed
brown color indicated by arrow head. Representative images are shown. Scale
bars represent 100mm. Expression of proinflammatory cytokines in epididymal
adipose tissue (B) was determined by real-time PCR and normalized to 18S
RNA. Bone marrow cells from HF-fed WT and CD47 deficient mice were isolated
and differentiated into macrophages. Migration of these cells were measured
basally and upon MCP1 (50 ng/ml) stimulation (C) using modified Boyden
Microchemotaxis Chamber. Data are presented as mean ± SE (n=5-7
mice/group), *P<0.05 and **P<0.01.
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Figure 3.4 Liver lipid accumulation
CD47 deficiency prevents lipid accumulation in liver after HF diet feeding. Lipid
accumulation in liver from four groups of mice was determined by measuring liver
weight (A), staining liver sections by Oil-red-O (B), and quantification of
triglyceride from liver extracts (C). The representative images of Oil Red O
staining are shown. Scale bars represent 100 mm. Data are presented as mean
± SE (n=5-7 mice/group), *P<0.05.

93

94

Figure 3.5 Glucose and insulin tolerance tests
HF-fed CD47 deficient mice had improved glucose tolerance and insulin
sensitivity compared with HF-fed controls. Intraperitoneal glucose tolerance test
(A) and insulin sensitivity test (B) were performed in male CD47 deficient and
littermate control mice after 15 weeks of HF or LF feeding. Data are presented as
mean ± SE (n=5-7 mice/group), *P<0.05 vs. HF CD47-/-; #P<0.05; AUC: area
under the curve.
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Figure 3.6 Metabolic profiles of WT and CD47 deficient mice under either LF
or HF feeding conditions
Eight week old male CD47 deficient mice and wild type littermate controls were
fed with LF or HF diet for 16 weeks and individually housed in TSE PhenoMaster
chambers for indirect calorimetric analysis. Daily food intake (A) was measured
for 6 consecutive days. Energy expenditure (B) was normalized to total body
mass during both the light and dark cycles. Heat production (C), core body
temperature (D), and activity (E) were shown during both the light and dark
cycles. Data are presented as mean ± SE (n=4-5 mice/group), *P<0.05;
**P<0.01; ***P<0.001.
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Figure 3.7 Metabolic gene expression in skeletal muscle from LF or HF
feeding WT or CD47 deficient mice
After 16 weeks of LF or HF feeding, mitochondria DNA (mtDNA) copy number in
skeletal mice (A) from four groups of mice and expression of metabolic genes (B)
including acyl-CoA oxidase (ACO), fatty acid transporter protein (FATP1),
carnitine palmitoyltransferase 1b (CPT1b), UCP3, PGC-1a, COX I, COX III and
ATPsyn were measured by real-time PCR. Data are presented as mean ± SE
(n=5–7 mice/group), *P<0.05.
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Figure 3.8 Morphology and metabolic gene expression in BAT from LF or
HF fed WT or CD47 deficient mice
CD47 protein levels in brown adipose tissue from LF or HF fed WT mice by
immunoblotting (A) (Cropped blots were used); Representative images of HE
staining of brown adipose tissue (B) from LF or HF fed CD47 deficient and WT
mice. Images were obtained at x20. Scale bars represent 100mm; Percentage
lipid content in brown adipose tissue sections (C), as quantified using image
analysis software. Mitochondria DNA copy number by PCR (D) and expression of
metabolic genes (E) by real-time PCR. Data are presented as mean ± SE (n=5–7
mice/group), *P<0.05 and **P<0.01.
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Figure 3.9 cGMP or PKG signaling in BAT and skeletal muscle from LF or
HF fed WT or CD47 deficient mice
cGMP levels in brown adipose tissue (A) from LF or HF fed WT mice by direct
immunoassay; PKG-I protein levels in brown adipose tissue (B) from LF or HF
fed WT mice by immunoblotting (Cropped blots were used); cGMP levels in
skeletal muscle (C) from LF or HF fed WT mice by direct immunoassay; PKG-I
protein levels in skeletal muscle (D) from LF or HF fed WT mice by
immunoblotting (Cropped blots were used). Data are presented as mean ± SE
(n=5-6 mice/group), *P<0.05 and **P<0.01.
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Figure 3.10 Characterization of white adipose tissue depots in CD47
deficient mice challenged with HF diet
CD47 deficiency was associated with a significant reduction in adipocyte size in
subcutaneous (A) and epididymal (B) adipose tissue depots independent of diet
challenge as demonstrated by H&E staining. Representative images are shown.
Scale bars represent 100mm. Adipocyte size was quantified using a Nikon
Eclipse 55i microscope and Nikon NIS-Elements BR software. Each group
contained three mice. Three sections with 100 adipocytes each were measured
per mouse. Data are presented as mean ± SE. *P<0.05; **P<0.01; ***P<0.001.
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Figure 3.11 Adipogenesis and mitochondrial function of white adipocytes
Primary preadipocytes were isolated from white adipose tissue of eight week old
WT and CD47 deficient mice and differentiated into mature adipocytes for 8
days. WT and CD47 deficient adipocytes accumulated comparable levels of lipid
demonstrated by Oil Red O staining after 8 days of differentiation (A, B). CD47
deficient and control white adipocytes demonstrate comparable mitochondrial
function. A basic mitochondrial stress test using the Seahorse XF96 Flux
Analyzer demonstrates no significant difference in mitochondrial function
between CD47 deficient and control white adipocytes in response to assay
agents at specific time points (C). Basal respiration rates, ATP production, nonmitochondrial respiration, and maximal respiratory capacity (D) are presented as
pmol/min of oxygen in assay media. All values are normalized to protein/well.
Five to seven replicates were used for each group. OCR: oxygen consumption
rates.
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Figure 3.12 Regulation of lipid turnover by CD47
Eight week old CD47 deficient and wildtype littermate control mice were treated
with either CL 316,243 (β-agonist; 1mg/kg BW; i.p. injection) or saline (vehicle)
after a six hour fast. CD47 deficiency significantly increased plasma glycerol
levels basally and with β-agonist stimulation (A) (n=4-7/group). Epididymal
adipose tissue (EAT), subcutaneous adipose tissue (SAT), and brown adipose
tissue (BAT) were excised from eight week old CD47 deficient and wildtype
littermate control mice after a six hour fast (n=3 mice/group; all tissue samples
from each mouse were triplicated). Tissues were serum starved for 1 hour and
then treated with vehicle or 10µM isoproterenol for 2 hours. Glycerol release was
measured in the media by colorimetric kit. Lack of CD47 expression significantly
increased lipolysis indicated by glycerol content in the media in epididymal and
subcutaneous adipose tissue depots independent of treatment (B). Fully
differentiated 3T3-L1 adipocytes were serum starved, pretreated with either IgG
control or a CD47 functional blocking antibody clone B6H12 (2µg/mL) for 30
minutes, then stimulated with c-CPT-cGMP (200µM) or isoproterenol (positive
control; 10µM). After three hours, media was collected and glycerol release was
measured and normalized to cellular protein content. Treatment with c-CPTcGMP and CD47 functional blocking antibody significantly increased glycerol
release compared to controls in an additive manner (C). All in vitro experiments
were triplicated. Data are presented as mean ± SE; *P<0.05; **P<0.01;
****P<0.0001; #P<0.0001 compared to all groups. Ab: antibody; CL: CL 316,243;
Iso: isoproterenol; ns: no significance.
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Figure 3.13 FFA-dependent uncoupling in BAT mitochondria
Mitochondria were isolated from BAT of 8-week old CD47 deficient and WT
littermate control mice by differential centrifugation. Mitochondrial respiration
(presented as oxygen consumption) was measured using a Clark-type oxygen
electrode under sealed and isothermic conditions as previously described (255).
Over time, mitochondria were treated with various substrates to examine
individual bioenergetics states. Pyruvate and malate (PM; 5mM and 2.5mM,
respectively) were used to promote oxidation. ADP (120nmol) was used to
measure State III respiration and oligomycin (oligo; 1µM) was used to induce
State IV respiration. FFAs (60µM linoleic acid) were added to induce uncouplingmediated respiration and BSA (3%) was subsequently added to blunt FFAinduced uncoupling by sequestering FFAs. Last, FCCP was added to induce
maximal uncoupling. Representative oxygraph traces (A) are presented from WT
and CD47 deficient BAT mitochondria. Downward trends of the lines within the
graph indicate oxygen consumption. After the addition of each compound,
changes in oxygen consumption were quantified (B). Mitochondria isolated from
CD47 deficient BAT are highly uncoupled in response to FFA treatment, when
respiration is compared to FCCP-induced uncoupling. Data are presented as
mean ± SE (n=4 mice/group); ***P<0.001.
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Section 4: SPECIFIC AIM 2
4.1 Summary
Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of
metabolic syndrome, is driven by elevated oxidative stress and impaired
mitochondrial function in the presence of increased lipid. However, specific
signaling

mechanisms

initiating

these

events

are

largely

unknown.

Thrombospondin-1 (TSP1) activity through the transmembrane receptor CD47
has been previously implicated in the development of oxidative stress in rodent
hepatic ischemia reperfusion and transplantation models. The aim of our study
was to examine for the first time whether TSP1 and CD47 are involved in the
pathogenesis of diet-induced fatty liver by mediating oxidative stress. We
demonstrated that both TSP1 deficient and CD47 deficient mice challenged with
high fat (HF) diet for 16 weeks were protected against hepatic lipid accumulation,
inflammation, fibrosis, and oxidative stress typically associated with fatty liver
disease. Our studies also demonstrated that hepatic protein levels of TSP1 and
CD47 are both upregulated under HF conditions. In vitro studies show that TSP1
treatment induces reactive oxidative species (ROS) to levels comparable to free
fatty acids (FFAs) in human hepatocyte cell line (HepG2 cells); however,
functional blocking antibodies against CD47 attenuated TSP1-induced ROS.
Similarly, CD47 deficient primary hepatocytes were protected from FFA and
TSP1-induced ROS. Collectively, results from our studies suggest that increased
hepatic TSP1 and CD47 expression under HF conditions may contribute to the
development of NAFLD by augmenting ROS production.
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4.2 Introduction
Nonalcoholic fatty liver disease (NAFLD) is becoming increasingly
common due to elevated levels of visceral adiposity and obesity. In the western
world, between 10-15% of lean individuals and approximately 70% of obese
individuals are affected (73, 270). Unfortunately, increased lipid accumulation
within the liver is directly linked to whole body insulin resistance and exacerbates
the risk of developing nonalcoholic steatohepatitis (NASH), a full-blown
inflammatory and fibrogenic response, which contributes to cirrhosis and
hepatocellular carcinoma (HCC) (7).
Recent studies have demonstrated that oxidative stress precedes the
development of hepatic insulin resistance, lipodystrophy, and inflammation in
high fat-fed rodent models (97, 163, 180). Further, reactive oxidative species
(ROS) stimulate

inflammatory signaling

pathways,

reduce

mitochondrial

biogenesis, and impair the adaptive responses of the mitochondria to manage
increased lipid burden under obese conditions (179, 221, 243). However, the
specific mechanisms responsible for these initiating events have not been
determined. It is suggested that identifying mechanisms which protect against
ROS production and preserve mitochondrial function in the presence of
increased energy substrate would be a viable therapeutic targets for NAFLD.
CD47, a ubiquitously expressed transmembrane cell surface receptor,
regulates several pathways including self-recognition and vascular function (28,
193). Our group and others have identified TSP1 as a contributor to metabolic
dysfunction in high fat (HF) diet-induced obesity (53, 100, 128, 144, 162, 268).
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Similarly, recent studies from our laboratory suggest CD47 deficiency could be
protective against obesity-associated complications (156). Upon activation by
picomolar concentrations of thrombospondin-1 (TSP1), CD47 signaling promotes
ROS production and inflammation in hepatic ischemia reperfusion injury and liver
transplantation models (105, 293). Although the TSP1-CD47 interaction has
been implicated in other hepatic conditions and both have been shown to
contribute to metabolic dysfunction, this signaling mechanism has never been
explored in the progression of NAFLD.
The aim of our study is to determine whether TSP1 and CD47 interaction
contributes to ROS production in the development of NAFLD. We determined
both TSP1 and CD47 expression is upregulated in the liver under HF conditions.
Further, we demonstrated that TSP1 deficiency and CD47 deficiency similarly
protected mice from obesity associated fatty liver disease. Moreover, in vitro
studies show TSP1-induced ROS is partially facilitated through CD47 and
contributes to hepatocyte-specific oxidative stress. This study suggests that the
TSP1-CD47 interaction could potentially be a viable therapeutic target for dietinduced fatty liver.
4.3 Results
4.3.1 TSP1 deficiency protects mice from diet-induced fatty liver
It has been well established that expression of TSP1, the most potent
ligand of CD47, is significantly elevated in plasma and adipose tissues under
obese conditions (268, 277); however TSP1 levels in the liver have not been
determined. In our studies, TSP1 protein (Figure 4.1 A; P<0.05) and mRNA
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(Figure 4.1 B; P<0.05) levels were significantly upregulated in whole liver tissue
from wildtype mice after four month HF feeding compared to LF fed controls. In
addition, our lab and others have established a pathological role of TSP1 in
obesity and metabolic dysfunction (128, 144, 268). Yet, the effects of TSP1 on
obesity-associated fatty liver disease have never been reported. In our studies,
TSP1 deficient and wildtype controls (WT) were challenged with either LF or HF
diet for 16 weeks. Although TSP1 deficiency did not reduce final body weights
(Figure 4.1 C) or liver weights (Figure 4.1 D) after 16-week HF feeding, HF-fed
TSP1 deficient mice demonstrated a significant reduction in hepatic triglyceride
content (Figure 4.1 E; P<0.01) represented by H&E staining (Figure 4.1 F).
Further, TSP1 deficiency was associated with significantly reduced TNFα and
collagen IαI mRNA levels under HF diet conditions (Figures 4.1 G, H; P<0.05)
indicating a protective

role

against

deficiency

alters

hepatic inflammation and fibrosis,

respectively.
4.3.2 TSP1

hepatic

genes

related

to

lipid

metabolism
To examine what mechanisms in the liver may be contributing to reduced
lipid accumulation in TSP1 deficient mice, several metabolic pathways were
examined by qPCR. Fatty acid oxidation genes, peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC1α), the coactivator responsible for
regulating mitochondrial function, peroxisome proliferator-activated receptor
alpha (PPARα), the key nuclear receptor driving expression of other fatty acid
oxidation genes, and carnitine palmitoyltransferase 1A (Cpt1A), an enzyme
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responsible for the rate limiting step of fatty acid oxidation, were measured and
no differential gene expression was observed between all four groups. This
suggests increased lipid oxidation is not contributing to reduced hepatic lipid
content (Figure 4.2 A).

Key genes associated with gluconeogenesis,

phosphoenolpyruvate carboxykinase (Pepck) and glucose-6-phosphatase (G6P),
were downregulated in HF-fed TSP1 deficient mice (Figure 4.2 B; P<0.05 for
G6P), suggesting enhanced gluconeogenesis is not driving reduced hepatic lipid.
Interestingly, expression of peroxisome proliferator-activated receptor
gamma (PPARγ) and sterol regulatory element-binding protein 1c (SREBP1c),
two positive regulators of lipogenesis and lipid storage, were significantly
reduced in the livers of HF-fed TSP1 deficient mice compared with HF-fed
controls (Figure 4.2 C; P<0.01 and P<0.05, respectively). Moreover, mRNA
levels of microsomal triglyceride transfer protein (MTTP), a critical regulator of
lipoprotein assembly and triglyceride secretion, was also measured. HF-fed
TSP1 deficient mice demonstrated a significant reduction in MTTP (Figure 4.2 D;
P<0.0001), which would suggest that enhanced lipoprotein/triglyceride secretion
is not preserving hepatic morphology under HF conditions. Finally, key genes
implicated in fatty acid uptake in fatty liver disease models were measured.
Although a slight reduction, no significant differences were observed in CD36 or
fatty acid transport proteins (FATPs) 2 and 5 mRNA levels (Figure 4.2 E).
4.3.3 CD47 deficiency protects mice from diet-induced fatty liver
CD47 is a potent receptor for TSP1. To explore its role in a fatty liver
disease phenotype, CD47 deficient and wildtype littermate controls (WT) were
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randomized into groups and challenged with either a LF or HF diet for 16 weeks.
Consistent with our previously published reports using age-matched CD47
deficient and C57BL/6 control mice (156), HF-fed CD47 deficient mice gained
significantly less body weight (Figure 4.3 A; P<0.01) and had significantly smaller
livers by absolute weight (Figure 4.3 B; P<0.0001) and as a percentage of body
weight (Figure 4.3 B; P<0.01) when compared with HF-fed wildtype littermate
controls after 16 weeks of diet challenge. All groups consumed comparable
amounts of food daily and no significant differences in plasma lipid parameters
(free fatty acids, triglyceride, or total cholesterol levels) were observed (data not
shown). In addition, liver morphology and function was examined. Histological
H&E and oil red O staining (Figure 4.3 C, D) confirmed the absence of CD47
significantly reduced hepatic triacylglycerol content (Figure 4.3 E; P<0.05) after
16 weeks of HF diet challenge. Moreover, plasma alanine aminotransferase
(ALT) levels, a common indicator of hepatic dysfunction, were significantly
reduced in HF-fed CD47 deficient mice compared with HF controls (Figure 4.3 F;
P<0.01). These studies suggest CD47 deficiency protects mice against dietinduced fatty liver.
4.3.4 CD47

deficiency

reduces

obesity-associated

hepatic

inflammation and fibrosis
It has been well-characterized that diet-induced fatty liver is associated
with elevated inflammation which drives the development of fibrosis (263). It has
also been shown that CD47 deficiency protects against adipose tissue and
systemic inflammation under obese conditions, but effects on the liver have not
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been explored. To further characterize the liver phenotype observed in our mice,
immunohistochemistry (IHC), collagen staining, and quantitative PCR (qPCR)
were completed. It has been suggested that fatty liver-associated inflammation is
due to an increase in macrophage recruitment rather than resident macrophages
(Kupffer cells) (174). Although IHC demonstrates macrophage presence by
staining of F4/80 in all groups (Figure 4.4 A), CD47 deficiency significantly
reduces the number of macrophages present within the livers of HF-challenged
mice to levels comparable to the LF groups (Figure 4.4 B; P<0.05). Moreover,
qPCR confirmed HF-fed controls had elevated levels of inflammatory markers
TNFα, MCP1, and CD11c, while CD47 deficiency in HF-fed animals completely
restored inflammatory markers to that of the LF control animals (Figure 4.4 C;
P<0.05).
Further, HF-fed controls have two-fold more collagen deposition as
demonstrated by Sirius Red staining compared with HF-fed CD47 deficient mice
(Figures 4.5 A, B; P<0.05). We confirmed a reduction in fibrosis with qPCR.
Consistently, HF-fed controls had elevated levels of collagen IαI, collagen III, and
collagen IV gene expression (Figure 4.5 C; P<0.05), which have previously been
identified as fibrotic markers of NAFLD (34, 64, 229). Together, these data show
HF-fed CD47 deficient mice exhibit reduced diet-induced hepatic inflammation
and fibrosis.
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4.3.5 CD47 deficiency regulates lipogenic gene expression in a dietinduced fatty liver model
To further elucidate the mechanism for reduced lipid deposition within the
livers of HF-fed CD47 deficient mice, qPCR was utilized to examine expression
of fatty acid oxidation, gluconeogenic, triglyceride secretion, lipogenic, and fatty
acid uptake genes. Expression of fatty acid oxidation genes, PGC1α, PPARα,
and Cpt1A, were comparable between the four groups (Figure 4.6 A), suggesting
increased fatty acid oxidation is not contributing to reduced lipid deposition in the
liver of HF-fed CD47 deficient mice. Second, key genes associated with
gluconeogenesis, Pepck and G6P, were measured and showed no differential
regulation between genotypes (Figure 4.6 B). Consistent with HF-fed TSP1
deficient mice (Figure 4.2 C), HF-fed CD47 deficient mice exhibited a significant
reduction in both lipogenic genes, PPARγ and SREBP1c (Figure 4.6 C; P<0.01).
No differential expression of MTTP was observed indicating reduced lipid within
the liver is not a result of elevated triglyceride secretion to peripheral tissues
(Figure 4.6 D). Finally, genes involved in fatty acid uptake were measured. CD47
deficiency was associated with a significant reduction in CD36 mRNA levels in
HF-fed mice (P<0.0001); however, no differences were observed in fatty acid
transport proteins (FATPs) 2 and 5 (Figure 4.6 E).
4.3.6 TSP1 and CD47 deficiency reduces hepatic oxidative stress in a
diet-induced fatty liver model
ROS production has been shown to play a causal role in the progression
of NAFLD which results in inflammation and insulin resistance (19). Our studies
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demonstrate a significant reduction in oxidative stress in both TSP1 and CD47
deficient livers in a diet-induced fatty liver model. TSP1 deficiency under HF
conditions was associated with a reduction in the cleavage of H2DCFDA to DCF,
a common indicator of oxidative stress, in liver tissue homogenates (Figure 4.7
A; P<0.001). Lipid peroxidation, the degradation of lipids by free radicals, is
another cellular source of ROS that has been implicated in the pathogenesis of
fatty liver disease (271). Malondialdehyde (MDA), a potent byproduct of
incomplete lipid peroxidation, was measured in whole liver tissue as an indication
of lipid peroxidation. As expected, HF diet challenge was associated with a
significant increase in MDA levels (P<0.001); however HF-fed TSP1 deficient
mice demonstrated a significant reduction in hepatic MDA accumulation
compared with HF-fed controls (Figure 4.7 B; P<0.05). Together, these results
suggest that TSP1 deficiency is protective against the development of hepatic
ROS under obese conditions.
Similarly, HF-fed CD47 deficient mice exhibited a significant reduction in
ROS production compared to HF-fed controls demonstrated by the production of
DCF in whole liver tissue homogenates (Figure 4.7 C; P<0.05). Moreover, HF-fed
controls exhibited a two-fold increase in lipid peroxidation compared with LF
controls as indicated by levels of MDA within whole liver tissue (P<0.05).
However, HF-fed CD47 deficient mice are protected against hepatic lipid
peroxidation (Figure 4.7 D; P<0.05). Together, these studies suggest CD47
deficiency is protective against oxidative stress in the liver under HF conditions.
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4.3.7 CD47 expression is upregulated by high fat diet in the liver
Diet regulation of CD47 expression in the liver is largely unknown. HepG2
cells, an immortalized human hepatoma cell line, are commonly utilized as an in
vitro model for hepatic metabolic function. We were able to demonstrate that
CD47 expression is significantly elevated in a dose dependent manner after 24hour fatty acid treatment (Figure 4.8 A; P<0.01 with 50µM palmitate treatment,
P<0.0001 with 200µM palmitate treatment). In addition, we isolated primary
hepatocytes from C57BL6/J mice after 3, 7, and 14 days of LF or HF feeding.
CD47 protein expression was significantly increased on hepatocytes from HF-fed
mice after just 14 days of diet challenge (Figure 4.8 B; P<0.05). These data
suggest CD47 protein expression is upregulated by over-nutrition in the liver.
4.3.8 CD47 blockade and deficiency are associated with reduced FFA
and TSP1-induced ROS development in hepatocytes in vitro
To define the role of CD47 in hepatocyte function, we performed in vitro
studies utilizing purified full length TSP1 and fatty acid treatments. It has been
previously reported that acute treatment with FFAs triggers ROS production in
HepG2 cells (44, 59, 80). Consistent with the literature, we demonstrate an
increase in ROS production after 6-hour palmitate treatment in HepG2 cells as
indicated by the fluorescent probe DCF (Figure 4.8 C; P<0.05). Similarly, 6-hour
TSP1 treatment was sufficient to induce comparable levels of ROS in these cells
(Figure 4.8 C; P<0.05). GST had no effect on ROS production. However,
pretreatment with a CD47 functional blocking antibody clone B6H12 (2µg/mL) for
30 minutes prior to TSP1 treatment attenuated ROS production (Figure 4.8 D;
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P<0.05), suggesting TSP1-induced ROS is partially facilitated through CD47
activation.
To confirm the role of CD47 in ROS production within hepatocytes,
primary hepatocytes were isolated from age-matched male wildtype, CD47
deficient, and CD36 deficient mice. CD36 deficient primary hepatocytes were
also included within this study because some actions of TSP1 in other cell types
are facilitated through the scavenger receptor/fatty acid transport protein, CD36,
and hepatocyte expression of CD36 positively correlates with lipid accumulation
in the liver (104, 129). After 6-hour palmitate treatment, both CD47 deficient and
CD36 deficient primary hepatocytes demonstrated a significant reduction in ROS
production compared to wildtype cells (Figure 4.8 E; P<0.05). Interestingly, after
TSP1 treatment for 6 hours, only CD47 deficient hepatocytes exhibited protection
from ROS production (Figure 4.8 F; P<0.01). These data support the idea that
CD47 deficiency is protective against both fatty acid and TSP1-induced ROS
production within hepatocytes; however, TSP1 activity is dependent on CD47.
4.4 Discussion
CD47, a transmembrane receptor, has been extensively studied in
regards to cancer and immune cell function and migration (28, 193). In addition,
CD47 activation by thrombospondin 1 (TSP1), a matricellular protein, contributes
to oxidative stress in a number of tissues (107, 109). Although oxidative stress
has been implicated as a causal mechanism for the development of nonalcoholic fatty liver disease (NAFLD) (122, 189, 199), the role of the TSP1-CD47
axis in hepatic metabolic dysfunction has never been defined. The aim of this
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study was to examine whether TSP1 and CD47 are involved in the pathogenesis
of diet-induced fatty liver by mediating ROS production. In the current study, we
demonstrated for the first time in two separate cohorts of mice that TSP1 and
CD47 deficiency protected against hepatic lipid accumulation and suppressed
fatty liver-associated inflammation and fibrosis in a HF diet-induced NAFLD
model. Moreover, both genotypes were associated with a significant reduction in
hepatic ROS production despite HF diet challenge. In addition, hepatic TSP1 and
CD47 protein expression positively correlate with HF diet and in vitro studies
confirmed that CD47 deficiency or pharmacological blockade significantly
reduced oxidative stress associated with acute fatty acid or TSP1 treatment.
Together, our studies suggest that both TSP1 and CD47 deficiency protect
against hepatic lipid accumulation in a rodent NAFLD model by suppressing ROS
production.
In the current studies, TSP1 deficient mice when challenged with HF diet
did not exhibit reduced body weight or liver size, despite a reduction in liver
triglyceride content (Figure 4.1). On the other hand, CD47 deficient mice were
significantly

protected

against

diet-induced

obesity

and

demonstrated

significantly smaller livers after HF diet challenge (Figure 4.3). Differences in
body weight and liver size suggest unique mechanisms within TSP1 deficient and
CD47 deficient animals that account for altered lipid partitioning under HF
conditions. Although evidence is clear linking the TSP1-CD47 axis to ROS
production in the liver, independent effects of TSP1 and CD47 on lipid
homeostasis require further investigation.
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Hallmarks of NAFLD progression include the accumulation of ectopic fat
within hepatocytes, activated inflammatory pathways, and fibrogenesis. In our
current studies, both TSP1 deficient and CD47 deficient animals were
significantly protected against hepatic lipid deposition. To further characterize the
potential mechanisms leading to the protective effects of TSP1/CD47 deficiency,
a number of genes that regulate lipid metabolism were examined in both groups
of animals. In both in vivo studies, no changes in genes relating to fatty acid
oxidation or gluconeogenesis were observed, suggesting that reduced lipid
accumulation in livers from HF-fed TSP1 deficient and CD47 deficient mice was
not due to increased fuel utilization or enhanced glucose production from fatty
acid byproducts.
Hepatic CD36 levels were suppressed in HF-fed TSP1 deficient mice and
significantly downregulated in HF-fed CD47 deficient mice, suggesting a potential
reduction in fatty acid uptake; however, no changes were observed in liver
specific fatty acid transport proteins 2 and 5 (FATP2, FATP5) in either group of
animals. Because CD36 is a scavenger receptor, the reduction in mRNA levels
could be a result of reduced immune cell infiltration into the liver tissue instead of
a reduction in hepatocyte-specific expression. Therefore, reduced fatty acid
uptake might not be responsible for reduced hepatocyte intracellular lipid
accumulation. Interestingly, mRNA levels of MTTP were significantly reduced in
HF-fed TSP1 deficient livers and no change was observed in HF-fed CD47
deficient livers; nevertheless, enhanced lipoprotein/triglyceride secretion is not
contributing to reduced hepatic lipid. Further analysis demonstrated that
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expression of lipogenic genes, SREBP1c and PPARγ, were significantly reduced
in both HF-fed TSP1 deficient and CD47 deficient animals. Further analysis
demonstrated that downstream target genes of SREBP1c, including Scd1 and
Fasn, were not differentially regulated. Together these results suggest that
reduced de novo lipogenesis might be a contributor to decreased liver fat
accumulation. Because SREBP1c activation is driven by insulin, these findings
further support the claim that CD47 deficient mice have increased insulin
sensitivity due to the reduction in plasma insulin levels after fasting (data not
shown).
As expected with a reduction in lipid accumulation, both TSP1 deficient
and CD47 deficiency were associated with significant protection from hepatic
inflammation under HF conditions. Both TSP1 and CD47 have previously been
implicated in obesity-associated inflammation and immune cell recruitment into
adipose tissue as a result of HF diet challenge (128, 144, 156). However, the
effects of the TSP1-CD47 interaction in diet-induced hepatic inflammation have
never been explored. Similar to NAFLD, other disease states such as hepatic
ischemia reperfusion injury and liver transplantation models are driven by
inflammation (131, 279). Previous reports have linked CD47 deficiency to
reduced inflammation in hepatic ischemia/reperfusion models and liver
transplantation models (105, 293). Xiao et al. established that CD47 blockade
with a monoclonal antibody in a rat liver transplantation model reduced TSP1mediated expression of several key cytokines (TNFα, IL-1β, and IL-6) that
correlate with liver injury (293). In addition, targeting CD47 with a functional
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blocking antibody in steatotic rat livers attenuated ischemia reperfusion injury by
suppressing inflammatory responses (292). In alignment with these reports, our
in vivo studies demonstrated that both TSP1 and CD47 deficiency were
associated with a significant attenuation of inflammation in a diet-induced fatty
liver model.
Fibrogenesis, or increased collagen deposition within the liver, is a result
of activated hepatic stellate cells (HSCs). The presence of fibrosis within the liver
is indicative of more severe cases of nonalcoholic steatohepatitis (NASH) and is
associated with increased likelihood of developing full blown cirrhosis. HSCs are
activated by increased lipid accumulation within hepatocytes and in response to
proinflammatory cytokines released by resident immune cells (Kupffer cells) and
hepatocytes (289, 295). In our study, the presence of significant collagen
deposition in the liver is observed in HF-fed WT mice; however, both TSP1 and
CD47 deficiency are associated with downregulated collagen mRNA levels. Most
likely, this reduction is secondary to the reduction of lipid accumulation and
inflammatory markers observed in the livers of TSP1 and CD47 deficient mice.
Recent studies propose that oxidative stress precedes the onset of
NAFLD and drives the development of inflammation, lipid mishandling, and
insulin resistance (97). Several mechanisms within the liver may contribute to a
deleterious oxidative environment during the development of NAFLD. Our in vitro
studies utilizing HepG2 cells and primary hepatocytes confirm our in vivo findings
that TSP1-CD47 contributes to hepatocyte ROS production, yet the mechanism
has yet to be determined.

126

The

most

common

contributor

to

cytotoxic

oxidative

stress

is

mitochondria-derived ROS from compromised substrate oxidation and inability to
manage lipid burden (180). In addition, reduced expression and impaired function
of antioxidant enzymes augment intracellular oxidative damage (76, 272). Gene
expression analysis of downstream targets of Nrf2, a master regulator of
antioxidant enzymes, shows no differential regulation in HO-1, GST, or NQO1
(data not shown). This suggests that preservation of antioxidant pathways are
not contributing to our reduction in ROS. Interestingly, previous work by Csanyi
et al. and Yao et al. demonstrated TSP1 directly activates superoxide production
via NADPH oxidases (NOXs) in multiple cell culture models (52, 298); however
these effects were presented independent of CD47 activation. In our model, we
clearly demonstrated that lack of TSP1 and its receptor, CD47, reduced ROS
levels and that acute treatment with TSP1 induced ROS production to levels
similar to FFAs which was partially attenuated by a CD47 functional blocking
antibody. Our studies are consistent with previous reports presenting TSP1 as a
unique, extracellular ligand that may modulate the intracellular oxidative
environment. These effects may be through multiple mechanisms - direct
activation of oxidative enzymes, such as the NOX family, and through CD47mediated pathways.
In addition to CD47, CD36 is another receptor for TSP1. It has been
shown that uptake of myristic acid via the fatty acid translocase activity of CD36
was inhibited by TSP1 in endothelial cells (104). To further determine whether
the effects on ROS production in hepatocytes were specific to CD47, CD47
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deficient primary hepatocytes as well as CD36 deficient primary hepatocytes
were utilized for in vitro studies. Interestingly, we found that both CD47 and
CD36 deficiency reduced palmitate-stimulated ROS production, yet only CD47
deficiency protected against TSP1-induced ROS production. Without changes of
CD36 levels on CD47 deficient hepatocytes (data not shown), the mechanism of
reduced palmitate-stimulated ROS production in CD47 deficient hepatocytes is
unknown and warrants further investigation.
In conclusion, our studies suggest a novel role for the TSP1-CD47
interaction in the development of fatty liver-associated oxidative stress. Because
hepatic levels of TSP1 and CD47 were elevated under high fat conditions (Figure
4.1, 4.8), we believe TSP1-mediated ROS production through CD47 activation
could potentially augment the noxious cellular environment commonly observed
in obesity-induced fatty liver models. These findings expand the pathological
implications of TSP1-CD47 signaling to include obesity-associated fatty liver
disease.
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Figure 4.1 Liver phenotype of TSP1 deficient and control mice after 16 week
LF/HF diet challenge
WT mice were fed with LF or HF diet for 16 weeks and whole liver tissue TSP1
protein levels (A) and mRNA levels (B) were determined. Body weights (C) and
liver weights (D) are presented from WT and TSP1 deficient mice challenged
with either LF or HF diet for 16 weeks. Hepatic TG levels were measured by
commercial kit (E) and lipid accumulation in the liver was visualized with H&E
staining in all four groups of mice (F). Representative images are shown. Scale
bars represent 1000µm. Gene expression of the proinflammatory cytokine,
TNFα, and Collagen 1α1 were determined by real-time PCR and the delta CT
method (G, H) (n=10-15 mice/group). Data are presented as mean ± SE,
*P<0.05, **P<0.01, ****P<0.0001. LF: low fat; HF: high fat; WT: wildtype; TG:
triglyceride
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Figure 4.2 Metabolic gene expression in the livers of TSP1 deficient and WT
controls after 16 week LF/HF feeding
mRNA levels of genes involved in several hepatic metabolic pathways including
fatty acid oxidation (A), gluconeogenesis (B), lipogenesis (C), TG secretion (D),
and fatty acid uptake (E) were measured by real-time PCR and the delta Ct
method (n=10-15 mice/group). Data are presented as mean ± SE, *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001. FA: fatty acid; TG: triglyceride.
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Figure 4.3 Liver phenotype of CD47 deficient and control mice after 16
week LF/HF diet challenge
Body weights (A) and liver weights (B) are presented from WT and CD47
deficient mice challenged with either LF or HF diet for 16 weeks. Lipid
accumulation in liver from four groups of mice was visualized by H&E (C) and oil
red O staining (D). Representative images are shown. Liver triglyceride levels
were quantified (E) and plasma ALT levels were measured by commercial kit as
an indicator of hepatic function (F) (n=7-11 mice/group). Scale bars represent
1000µm. Data are presented as mean ± SE, *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001. ALT: alanine aminotransferase; BW: body weight; LF: low fat; HF:
high fat; WT: wildtype; TG: triglyceride.

134

135

Figure 4.4 Obesity-associated hepatic inflammation
Hepatic macrophage content was determined by anti-F4/80 staining (A). The
positive staining is represented by a brown color and indicated by white arrow
heads. Representative images for all four groups are shown. Scale bars
represent 1000µm. The percent of total area positively stained (B) was
determined using threshold features of the NIS Elements software by Nikon
Instruments. Gene expression for proinflammatory cytokines in the liver (C) was
determined by real-time PCR and the delta CT method (n=7-11 mice/group).
Data are presented as mean ± SE, *P<0.05, **P<0.01.
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Figure 4.5 Obesity-associated hepatic fibrosis
Collagen deposition in the liver was determined by Sirius red staining (A). The
positive stain is represented by a pink color and indicated by white arrow heads.
Representative images for all four groups are shown. Scale bars represent
1000µm. The percent of total area positively stained (B) was determined using
features of the NIS Elements software by Nikon Instruments. Gene expression
for collagen (C) in the liver was determined by real-time PCR and the delta CT
method (n=7-11 mice/group). Data are presented as mean ± SE, *P<0.05.
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Figure 4.6 Metabolic gene expression in the livers of CD47 deficient and WT
controls after 16 week LF/HF feeding
Expression of metabolic genes involved in (A) fatty acid oxidation, (B)
gluconeogenesis, (L) lipogenesis, (D) triglyceride secretion, and (E) fatty acid
uptake were measured by real-time PCR and the delta Ct method (n=7-11
mice/group). Data are presented as mean + SE, *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001.
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Figure 4.7 Hepatic oxidative stress
ROS was determined by the abundance of DCF and the levels of the lipid
peroxidation byproduct, MDA, in whole liver tissue homogenates from both
cohorts of mice. HF-fed TSP1 deficient mice (A, B) and CD47 deficient mice (C,
D) were protected against the production of ROS and MDA accumulation in
whole liver tissue. (n=7-11 mice/group). Data are presented as mean ± SE,
*P<0.05, **P<0.01, ***P<0.001. MDA: malondialdehyde; ns: no significance.
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Figure 4.8 FFA and TSP1-induced ROS development in hepatocytes in vitro
HepG2 cells were cultured and treated with BSA only, 50µM palmitate, or 200µM
palmitate for 24 hours. CD47 expression in cell lysates was determined by
western blotting (A). Wildtype mice were fed with either LF or HF diet for 3, 7, or
14 days and primary hepatocytes were isolated to examine CD47 levels by
western blotting (B) (n=3 mice/group). HepG2 cells were seeded at a density of
1x104/well and primary hepatocytes were seeded at a density of 2x104/well of a
white, clear-bottom 96-well cell culture plate for ROS quantification. Treatment
media for HepG2 cells included serum-free MEM + 0.5% BSA + 1% penicillinstreptomycin to avoid residual TSP1 expression. HepG2 cells were treated with
purified TSP1 (2µg/mL), BSA, or palmitate (200µM) for 6 hours and then DCF in
cells was measured by a fluorometric plate reader (C). HepG2 cells were
pretreated with either IgG control or a CD47 functional blocking antibody clone
B6H12 (2µg/mL) for 30 minutes and then treated with purified TSP1 (2µg/mL) for
6 additional hours. DCF was measured (D). Treatment media for primary
hepatocytes included serum-free Williams Media E + 0.5% BSA + 1% penicillinstreptomycin. Primary hepatocytes isolated from wildtype, CD47-/-, or CD36-/mice were treated with palmitate (200µM) (E) or purified TSP1 (2µg/mL) (F) for 6
hours and ROS production indicated by DCF was measured. Data are presented
as mean ± SE (n= 3 experiments), *P<0.05, **P<0.01, ****P<0.0001. Ab;
antibody; LF: low fat; HF: high fat; PA: palmitate; BSA: bovine serum albumin;
RFU: relative fluorescence unit.
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Section 5: GENERAL DISCUSSION
5.1 Summary
Literature

suggests

that

identifying

mechanisms

that

augment

inflammation, oxidative stress, and mitochondrial dysfunction in metabolic tissues
may be a viable therapeutic target for obesity and its associated complications.
The studies included in this dissertation are the first to provide evidence that
CD47 may be a novel mechanism contributing to metabolic dysfunction. In
addition to its well-established functions, we have demonstrated a unique
functional role of CD47 in metabolic tissues including white and brown adipose
tissue, skeletal muscle, and the liver, which are exhibited in Figure 5.1. The
central hypothesis of these studies is that CD47 contributes to obesity-associated
metabolic dysfunctions through diverse mechanisms including inflammation,
energy utilization, and TSP1-mediated oxidative stress. Specifically, we
hypothesized that lack of CD47 would protect against obesity-associated
inflammation, preserve healthy glucose homeostasis, and preserve energy
homeostasis despite high fat diet challenge. In addition, we hypothesize that the
TSP1-CD47 axis would lead to increased hepatic oxidative stress within a fatty
liver model.
In our current studies, CD47 deficiency was consistently associated with a
significantly leaner phenotype. Unlike a previous report which suggested that the
lean phenotype in CD47 deficient mice under basal conditions was attributed to
enhanced skeletal muscle function (74), we saw no change in several genes
critical for enhanced mitochondrial respiration in skeletal muscle within a diet-
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induced obesity paradigm. This led us to examine other metabolically active
tissues.
As described in Section 1, adipose tissue will expand through hypertrophy
and hyperplasia to sequester increased lipid burden under obese conditions.
Similarly, the liver is highly efficient at storing TG as a mechanism to protect
against dyslipidemia. Findings in both aims of this dissertation demonstrate that
CD47 deficiency is associated with smaller white adipocyte/adipose tissue depot
size, preserved BAT morphology, and reduced hepatic lipid accumulation despite
HF diet. It is likely that significantly reduced systemic, hepatic, and adipose tissue
inflammation is a result of reduced lipid accumulation and ultimately contributes
to the preserved glucose homeostasis and insulin sensitivity demonstrated in
CD47 deficient mice after 16 weeks of HF diet challenge.
As demonstrated in Section 3, CD47 deficiency enhanced BAT-dependent
energy expenditure through increased UCP1-mediated uncoupling. This specific
phenotype may be a result of preserved cGMP/PKG signaling within BAT.
Studies with isolated mitochondria confirmed that this increased energy
expenditure was driven by FFAs. Together, enhanced white adipose tissue
lipolysis perpetuated BAT activation by providing a constant energy source for
BAT energy expenditure. From these results, it could be hypothesized that
reduced hepatic lipid is also a result of increased peripheral energy needs. It has
not been determined whether increased fuel availability drives mitochondrial
function in BAT or whether increased energy needs induce rapid lipid turnover in
CD47 deficient mice.
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Our focus in Section 4 was the contribution of the TSP1-CD47 axis to
hepatic oxidative stress under HF conditions. It is difficult to clearly elucidate
whether suppressed hepatic ROS production in vivo is directly due to TSP1CD47 or a secondary effect of reduced hepatic lipid accumulation. However, in
vitro studies clearly show that TSP1 is capable of inducing ROS production in
hepatocytes and that blockade of CD47 attenuates this phenomenon. Because
these studies were completed in hepatocytes under basal conditions, this
supports the idea that TSP1-CD47 regulates hepatocyte oxidative stress
independent of obesity. We believe the increased TSP1 and CD47 protein
expression in the liver under HF conditions augments ROS production and that
these effects may be in conjunction and/or independent of lipid accumulation. In
addition, TSP1 deficiency had no effect on body weight/liver weight, whereas
CD47 deficiency was associated with a significant reduction in both. However,
both

models

consistently demonstrated

improvements

in

the

oxidative

environment of the liver, further supporting the idea this mechanism regulates
ROS production despite changes in global lipid partitioning. This leads us to
conclude that this signaling axis may be a novel mechanism contributing to fatty
liver disease-associated oxidative stress.
5.2 TSP1-independent Effects in CD47 Deficient Mice
The justification for our studies using CD47 deficient mice in a dietinduced obesity paradigm was to determine whether this specific cell receptor
was facilitating TSP1-mediated metabolic dysfunction under obese conditions.
Using the same experimental design for both cohorts of mice, TSP1 deficient and
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CD47 deficient mice were protected against obesity-associated complications
after 4-month HF diet challenge (100, 128, 144, 156). Several protective
phenotypes were shared between the two rodent models; however, some effects
were specific to each genotype. These effects are highlighted in Figure 5.2. In
both cohorts, mice were protected against obesity-associated inflammation,
glucose

intolerance,

and

hepatosteatosis

(144,

156).

Interestingly,

the

development of diet-induced obesity was not consistent between studies. TSP1
deficient mice were obese and metabolically healthy, whereas CD47 deficient
mice were resistant to obesity development which was attributed to enhanced
BAT-mediated energy expenditure. This suggests TSP1-independent effects in
CD47 deficient mice contribute to the observed phenotypes when challenged
with HF diet. Further studies are warranted to identify novel extracellular ligands
or lateral associations/cell receptor complexes for CD47 that may regulate the
development of obesity and energy expenditure.
5.3 Differential Effects of CD47 Deficiency on Metabolic Tissues
The effects of CD47 deficiency on metabolic tissues under obese
conditions is clearly illustrated in Figure 5.1. Although there seems to be a link
between CD47 deficiency and increased mitochondrial biogenesis in liver,
muscle, and adipose tissues, metabolic function is altered in a tissue-specific
manner in the absence of CD47. For example, CD47 deficiency enhances FFAmediated uncoupling and energy expenditure in BAT; however, the same effects
are not observed in WAT. While the studies included in this dissertation do not
define what mechanisms contribute to tissue-specific CD47 function, several
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factors have been identified that may contribute to the unique effects of CD47
deficiency in different tissues.
CD47 has been shown to undergo post-transcriptional modifications that
may account for varying functions in different metabolic tissues. As a result of
alternative splicing, four isoforms (1-4) of CD47 have been established that solely
differ by the length of their cytoplasmic tail (147, 212). These isoforms are highly
conserved between rodents and humans and vary in length from 3-36 amino
acids long. Isoforms 2 and 4 are most commonly observed. Rodent muscle fibers
have been shown to express isoforms 1, 2, and 3, while isoforms 2 and 3 are
predominantly expressed in the liver (212). To date, specific isoform expression
in adipose tissue has not been determined. CD47 may also undergo posttranslational modifications as well. Studies have determined that the extracellular
N-terminus of CD47 may be highly glycosylated in a tissue-specific manner (28),
which would affect the affinity of ligand binding and partner receptor interactions.
Tissue-specific isoform expression and structural changes suggest unique
functional roles of CD47.
In addition, lateral associations and intramembrane cell receptor
complexes including CD47 may differ between cell types. For example, CD47
has been shown to physically associate with the CD14/TLR4 complex in rodent
and human macrophages (246) and laterally associates with vascular endothelial
growth factor receptor-2 (VEGFR2) in endothelial cells (119). Downstream
functions of CD47 activation may be different depending on the lateral
associations in various cell types. Finally, varying expression levels of CD47 in
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different tissues (Figure 1.4) as well as the concentration of the specific CD47
ligand/binding partner will determine activity levels and function.
5.4 Potential Mechanisms Linking CD47 and Energy Expenditure
5.4.1 cGMP/PKG Signaling and Mitochondrial Function
In the current studies, efforts were made to identify the mechanism
contributing to increased mitochondrial number and function in metabolic tissues.
It is already well-established that CD47 activation has inhibitory effects on
cGMP/PKG signaling in the vasculature (109, 216, 218). These effects are also
depicted in Figure 1.4. Now, there are broader implications for cGMP/PKG
signaling in metabolic tissues and energy homeostasis. In 2004, Nisoli et al.
determined that the NO/cGMP pathway stimulated mitochondrial biogenesis and
that reduced eNOS-dependent production of NO in the liver and muscle resulted
in reduced mitochondrial area and density (188). Later in 2007, it was determined
that

inhibiting

the

phosphodiesterase-5

degradation
inhibitor,

of

cGMP

sildenafil,

pharmacologically

enhanced

whole

with

body

the

energy

expenditure in rodents and protected against diet-induced obesity (10). It was at
this time the NO/cGMP signaling cascade was deemed a critical component
necessary for systemic regulation of energy and fuel substrate homeostasis
through the promotion of mitochondrial biogenesis. Subsequent studies
confirmed elevated cGMP/PKG activity is protective against the development of
obesity, reduces obesity-associated inflammation, and promotes mitochondrial
biogenesis in skeletal muscle (9, 93, 185, 214, 260). Consistent with previous
reports (9, 74, 172), CD47 deficiency was associated with increased cGMP/PKG
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levels in skeletal muscle basally; however, no differences were observed under
HF conditions. This indicates cGMP/PKG-mediated skeletal muscle was not
contributing to the protective effects of CD47 deficiency.
Recently, a number of publications have highlighted the role of
cGMP/PKG signaling in healthy BAT expansion and energy metabolism. Similar
to HF-fed CD47 deficient mice, HF-fed PKG-transgenic mice exhibited
significantly smaller adipocytes and elevated mtDNA number in brown adipose
tissue and skeletal muscle (172). Haas et al. clearly showed that PKG deficiency
blunted brown adipogenesis (90). Further, Balkow et al. demonstrated that
cGMP/PKG is necessary for BAT mitochondrial-dependent energy expenditure
(14). In our studies, cGMP/PKG levels were reduced in HF-fed WT BAT as
expected; however CD47 deficiency was associated with increased levels of
cGMP/PKG despite HF diet challenge. This preservation of signaling correlated
with enhanced BAT function in CD47 deficient mice. Combining previous studies
with our findings, it suggests that impaired cGMP/PKG signaling within BAT
could play a causal role in obesity-associated metabolic dysfunction.
5.4.2 Regulation of Mitochondrial Function by c-Myc
Another potential mechanism linking CD47 to increased mitochondrial
function is the master regulatory gene, c-Myc. It has been shown that elevated cMyc expression positively correlates with enhanced mitochondrial function in
both hepatocytes and renal cells (143, 302). Interestingly, CD47 deficiency and
pharmacological blockade of CD47 significantly upregulate c-Myc expression in a
number of cell types (120, 220). Although the focus of these studies was on cell
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proliferation and self-renewal, additional studies are necessary to examine
whether the regulation of c-Myc expression by CD47 has any implications on
mitochondrial density or function in diet-induced obesity models.
5.4.3 BNIP3-dependent Mitochondrial Dysfunction
CD47 has also been shown to modulate intracellular Bcl2/adenovirus E1B
19-kDa interacting protein (BNIP3) activity within the cell (136). Upon activation
of CD47 by TSP1, BNIP3 migrates from the cell membrane to the mitochondria
and induces mitochondrial dysfunction and subsequent cell death in immune
cells (135, 136). Glick et al. demonstrated that BNIP3 is largely expressed in the
liver and may be involved in lipid metabolism (83); however, no studies to date
have examined the contribution of BNIP3-mediated mitochondrial dysfunction in
the liver under obese conditions.
5.5 Role of CD47 in Obesity-associated Inflammation
Although our studies identified a novel role for CD47 in energy
homeostasis, CD47 has previously been implicated in inflammatory stress
pathways and immune cell migration. The protective phenotype observed in HFfed CD47 deficient mice could suggest a potential dual function of CD47,
regulating both energy homeostasis as well as the inflammatory response to
increased lipid burden in obese conditions. Whether these effects on
inflammation are secondary to adiposity and lipid deposition has yet to be
determined.
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5.5.1 TLR4-dependent Mechanisms
It has been confirmed that CD47 is laterally associated with the CD14/tolllike receptor 4 (TLR4) complex in macrophages (246). This specific cell
membrane complex is responsible for recognizing pathogens, activating the
innate immune system in times of stress through a NFκB-dependent mechanism,
and promoting the secretion of several proinflammatory cytokines/chemokines
(153). Recently, reports suggest that in addition to lipopolysaccharide (LPS)
recognition, TLR4 can be activated by FFAs in macrophages and adipocytes and
may be a novel mechanism linking obesity and inflammation (236, 240). Other
groups have shown that TLR4 deficiency and loss-of-function mutations have no
conclusive effect on the development of adiposity, yet demonstrate an attenuated
inflammatory response in adipose tissue and reduced hepatic dysfunction (158,
236, 251). Additional studies have identified a complex role of CD47 in NFκBdependent inflammation. Some groups have shown that the lateral association
between CD47 and the CD14/TLR4 complex is necessary for LPS-mediated
activation of NFκB through the canonical TLR4 signaling pathway and that these
effects could be independent of TSP1 signaling. It has also been shown that
TSP1-mediated activation of CD47 is necessary to stimulate cytokine production
in macrophages (246), suggesting that the role of CD47 in inflammation may be
tissue and disease condition-specific. In our studies, we determined that whole
body CD47 deficiency reduced hepatic, adipose tissue-specific, and circulating
levels of proinflammatory cytokines, chemokines, and macrophage markers,
including TNFα, MCP1, and CD11c. Knowing many of these genes are
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downstream of TLR4 activation, additional studies are necessary to determine
whether CD47 expression augments inflammation in the presence of increased
FFA so commonly observed in obesity and fatty liver disease.
5.5.2 Activation and Migration of Immune Cells
For several years, it has been widely accepted that CD47 stimulates
immune cell activation and chemotaxis. Initially, it was determined that CD47
expression was required for neutrophil transmigration across the endothelial
layer into injured tissues (43, 49, 149). Subsequent studies have also shown that
T-cell migration into damaged tissues is also mediated by CD47 (11, 160). Not
until recently was it shown that CD47 may play a role in stimulating macrophages
to secrete proinflammatory cytokines, including IL-1β (246). Although these
studies were not completed in diet-induced obese rodent models, many of these
mechanisms are similar to the chronic inflammatory pathways commonly
observed in obesity. In addition to macrophage infiltration, T-cell and neutrophil
recruitment into adipose tissue have also been shown to perpetuate systemic
and adipose tissue-specific inflammation under obese conditions (62, 186).
Previous work from our lab in addition to the studies included in this
dissertation show that MCP1/CCR2 dependent recruitment of monocytes to
adipose tissue depots is significantly reduced in the absence of both TSP1 (144)
and CD47 (Figure 3.3). These findings are similar to the previously mentioned
studies that have shown a regulatory function of CD47 in the activation and
migration of immune cells in response to stress. Our in vitro migration studies
provide evidence to suggest CD47 may contribute to enhanced immune cell
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infiltration into adipose tissue and that these effects are independent of the
changes in adipocyte physiology. Future studies are critical for discerning
whether CD47 is augmenting adipose tissue dysfunction through dual
mechanisms – both immune response and alterations in energy storage.
5.5.3 Adipose Tissue Remodeling
A well-established source of inflammation in obesity is from adipose tissue
expansion and cellular stress under hypertrophic conditions (252). As adipocytes
expand to sequester lipid, stress is placed on the extracellular matrix (ECM).
Adipose tissue macrophages (ATMs) respond to this stress by secreting
cytokines and chemokines that recruit additional immune cells to the adipose
tissue depot (249). Few studies have examined the role of integrins, a molecular
link between the cell membrane and extracellular matrix proteins, in the
development of obesity. However, some suggest that integrins play a role in the
ECM remodeling required for adipocyte hypertrophy (63) and that impaired
integrin signaling is protective against diet-induced obesity development through
attenuated monocyte recruitment (68).
As a cell membrane protein, CD47 laterally associates with various
integrins in a number of cell types including chondrocytes, lymphocytes,
microglia, and smooth muscle cells (126, 198, 278, 300). It has even been
demonstrated that CD47 expression is necessary for integrin function and
integrin-mediated interactions with several ECM structural proteins including
fibronectin, vitronectin, and fibrinogen (146).

In this case, lack of CD47

expression could impair integrin-mediated expansion of adipose tissue resulting
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in smaller adipocytes and a suppressed proinflammatory profile typically
associated with obesity. To date, studies examining this interaction under obese
conditions have not been completed.
5.6 Study Limitations
5.6.1 Limitations of the Whole-body CD47 Deficient Mouse Model
All in vivo studies within Sections 3 and 4 were completed using wholebody CD47 deficient mice on a C57BL/6 background. As mentioned previously,
CD47 is ubiquitously expressed throughout the body and regulates a diverse
range of functions. When challenged with HF diet, CD47 deficient mice exhibit a
number of phenotypes. In order to examine the specific role of CD47 in adipose
tissue, inflammatory responses, or hepatic function, cell-specific knockdown of
CD47 would be incredibly beneficial to fully elucidate regulatory mechanism. At
this time, CD47 floxed mice are not available for cell type-specific knockdown of
CD47 via the Cre/LoxP system. An additional model that could be used to
examine the translational implications of CD47 in vivo includes antisense
oligonucleotides (ASOs) targeting highly conserved sequences of CD47 mRNA.
Although it has been shown that intraperitoneal injections of ASOs are dispersed
systemically, the highest accumulation is observed in the liver (81), providing an
alternative to global knockdown of CD47. The use of CD47-targeted oligomers
has been previously implemented in rodent ischemia/reperfusion, transplantation,
and radiation models.
In culture, ASOs and RNA interference mechanisms can also be used for
cellular knockdown of target genes. In addition, other technologies including the
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novel CRISPR/Cas system can identify specific DNA sequences and splice
genetic elements within target genes. In the current studies, primary cells
isolated from CD47 deficient mice (stromal vascular fraction and primary
hepatocytes) were used to confirm cell specific functions of CD47 in vitro.
5.6.2 Limitations

in

the

Exploration

of

Additional

CD47

Ligands/Interactions
To date, studies have primarily focused on CD47 and its interactions with
TSP1 and SIRPα. Our studies examined the TSP1-CD47 interaction in regards to
metabolic function; however, evidence suggests our findings related to energy
expenditure may be TSP1-independent. When challenged with HF diet for 16
weeks, TSP1 deficient mice exhibit similar adiposity compared with controls
(144) whereas CD47 deficient mice are protected from obesity development
through enhanced metabolic activity (156). It has been suggested that additional
ligands and binding partners could elicit some of the physiological functions
observed with CD47 activation. It is well established that other members of the
TSP family, including TSP2 and TSP4, have binding capability with CD47 but
requires much higher concentrations compared to TSP1 (102). Nevertheless,
these interactions have been established yet their tissue-specific functions
require additional exploration. Further, it has been proposed that novel ligands
could be propagating some of the effects of CD47 activation. Studies examining
protein-protein interactions through either yeast two-hybrid screening or affinity
purification could be completed to identify any unique interactions with CD47
under obese conditions.
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5.6.3 Limitations of the Diet-induced Fatty Liver Disease Model
It is critical that rodent models of NAFLD exhibit similar histology and
pathophysiology as fatty liver disease observed in humans. These models should
include significant hepatosteatosis, inflammation, and fibrogenesis as well as
other peripheral metabolic dysfunctions including obesity, insulin resistance,
hyperglycemia, and dyslipidemia (137). Several genetic, nutritional-based, and
combinational approaches have been used to study the development and
progression of NAFLD and more severe NASH (6). In our studies examining the
effects of CD47 deficiency on the development of NAFLD, we utilized a HF (60%
kcal from fat) diet-induced fatty liver model. In rodents, HF diet is sufficient to
induce

obesity,

insulin

resistance,

hepatosteatosis,

and

other

severe

comorbidities of NAFLD including fibrosis and necrosis. However, results are
highly variable depending on the rodent strain and differing fat compositions
found in commonly used HF diets. With this model, long-term dietary
interventions are necessary to elicit severe NASH progression.
An alternative to HF diet-induced fatty liver is the Amylin (AMLN) liver
NASH model. This diet is composed of 40% kCal from fat, 22% fructose, and 2%
cholesterol – most closely resembling the composition of a westernized diet high
in fat and added sugar. After ≥20 weeks of dietary intervention, severe NAFLD
and progression to NASH is observed in rodents (46). Although mice on this diet
gain weight, it is not significant or considered obese as demonstrated by 20 or
more weeks of HF-diet intervention only. In order to study fibrosis or progression
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from NASH to cirrhosis, many believe this rodent model serves as the best
histological and pathological representation of fatty liver disease in humans.
Another

common

model

of

NAFLD/NASH

in

rodents

uses

the

methionine/choline deficient (MCD) diet, which impairs hepatic fatty acid
oxidation and reduces VLDL secretion resulting in severe steatosis after just 4-10
weeks of dietary intervention (6, 299). In addition, inflammation, oxidative stress,
mitochondrial dysfunction, and fibrosis are much more severe in MCD-fed
rodents compared to HF-fed models (79); however, this intervention does not
mimic the peripheral metabolic dysfunction observed in HF-fed mice (257). On
the contrary, mice challenged with MCD diet for greater than 4-6 weeks exhibit
significant reductions in body weight. Future studies should consider the MCD or
AMLN diets as a model of NAFLD/NASH development in CD47 deficient mice to
separate hepatic lipid accumulation from the global effects on lipid deposition and
energy metabolism in vivo.
5.7 Future Directions
5.7.1 Effects of CD47 on cAMP Function in Metabolic Tissues
Activated cAMP-dependent protein kinase (PKA) via cAMP directly
regulates the rate-limiting step of lipolysis, hormone sensitive lipase (HSL), in
both WAT and BAT. This signaling cascade liberates FFAs through hydrolysis of
intracellular TG stores by phosphorylating HSL and promoting the remodeling of
lipid droplet proteins (132). It has been previously demonstrated that not only
cGMP, but also cAMP, levels are elevated in CD47 deficient tissues (106, 297).
The current studies propose that elevated cGMP/PKG signaling in brown adipose
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tissue and the liver promotes enhanced energy expenditure and non-shivering
thermogenesis; however, it is critical to explore the canonical cAMP/PKA
pathway. Additional studies examining cAMP signaling in CD47 deficient mice
under HF conditions are necessary to determine whether there is dual regulation
of secondary messenger signaling in CD47 deficient mice. Further, studies
inhibiting PKG and/or PKA are necessary to determine what contribution each
pathway has on lipid mobilization and utilization in CD47 deficient tissues. These
findings could identify CD47 as a novel regulatory mechanism for secondary
messenger signaling in metabolic tissues under obese conditions.
5.7.2 Pharmacological Blockade of CD47 in vivo
To support the clinical applications of targeting CD47 in obesity and its
associated metabolic complications, in vivo studies with wildtype mice treated
with a functional blocking antibody for CD47 or vehicle control should be
completed. To determine whether impaired CD47 signaling enhances metabolic
activity, animals could be treated after HF diet challenge to see whether
enhanced energy expenditure reduces adiposity post diet challenge. In addition,
mice could be treated simultaneously with HF diet challenge and metabolic
parameters could be assessed. These studies could potentially shed light on any
off-target effects of monoclonal antibody treatment targeting CD47 in vivo.
5.7.3 Determine

the

Specific

Effects

of

CD47

Expression

in

Hematopoietic Cells in vivo
It has been well characterized that CD47 is ubiquitously expressed
throughout the body on insulin-sensitive tissues such as muscle and liver. In HF-
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fed whole body CD47 deficient mice, both white and brown adipocyte
morphology and function was preserved, suggesting a role for CD47 in regulating
adipocytes

function

and

contribution

to

obesity–associated

metabolic

dysfunction. However, as previously highlighted in section 5.3.2, immune cells
express CD47 and may contribute to inflammatory-specific effects under HF
conditions. Therefore, it is necessary to determine whether CD47 deficiency in
non-hematopoietic cells, specifically adipocytes, protects mice from HF dietinduced obesity and other metabolic dysfunction in vivo by utilizing a bone
marrow transplantation approach to generate a chimeric mouse model. These
experiments would separate the effects of CD47 expression on energy
homeostasis and obesity-associated inflammation in metabolic tissues.
5.8 Clinical Significance
CD47 has been highly investigated as an anti-cancer therapeutic target,
because of its accessibility as a cell membrane receptor. Strong evidence
suggests that CD47 expression is significantly upregulated on tumor cells
ranging from non-Hodgkin lymphoma to acute myeloid leukemia as a protective
mechanism to avoid detection and phagocytosis by innate and adapted immune
responses (41, 157). Further, CD47 expression has been deemed a prognostic
marker in determining clinical outcomes for tumorigenesis. In a more recent
study in mice, the downregulation of phagocytic function by macrophages in
atherosclerotic lesions was attributed to the upregulation of CD47 expression and
activity in the vasculature (127). It has been demonstrated clearly in rodents and
non-human primates that functional blocking antibodies targeting CD47 are
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capable of triggering a phagocytic response and activating anti-tumor T-cell
responses in vivo without deleterious off-target effects (41, 148, 157, 264, 286).
With such promising results, four clinical trials have begun using monoclonal antiCD47

antibodies

against

both

solid

and

hematological

malignancies

(NCT02678338, NCT02641002, NCT02367196, NCT02663518).
In addition to the promising therapeutic potential of targeting CD47 in
cancer patients, our findings suggest an additional clinical implication for CD47.
Antagonizing CD47 with a functional blocking antibody may protect against
deleterious effects of metabolic dysfunction by preserving mitochondrial health
and function in states of overnutrition. Looking at preclinical animal models with
anti-CD47 antibodies, body weight is commonly reported as a measure of drug
tolerance and off-target effects. In many of these models, no changes in body
weight or body composition were reported and claimed as a positive indicator of
drug tolerance. From these data, it is very difficult to discern the effects of
pharmacological CD47 blockade on body weight and energy expenditure
because of differences in species, dosages, length of intervention, and varying
disease states and conditions. Preclinical studies are necessary to examine the
effects of pharmacological CD47 blockade in a diet-induced obesity model.
There are challenges to expanding the clinical implications of CD47 to
metabolic function. First, CD47 is highly expressed in the vasculature including
red blood cells, leukocytes, platelets, and endothelial cells. There is risk that
administration of functional blocking antibodies for CD47 would accumulate in the
circulation and very low levels would reach target tissues requiring highly
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concentrated doses or frequent administration. Second, it is feared that hemolytic
anemia or rapid clearance of native cells in circulation by phagocytosis would be
a result of antagonizing CD47. It has been shown that the SIRPα binding site on
CD47 is competitively blocked by commonly used functional blocking antibodies
(102). Impaired SIRPα-CD47 signaling reduces the body’s innate ability to
recognize foreign from native cell types (22) and ultimately could result in a
weakened response to infection. Current clinical trials will shed light on these
concerns.
5.9 Concluding Remarks
Together, these studies provide evidence to suggest CD47 may augment
metabolic dysfunction in a tissue-specific manner and that the pathological roles
of CD47 function could expand to include obesity and its associated
comorbidities. More broadly, in vivo studies demonstrate CD47 deficiency is
protective against diet-induced adiposity, reduces systemic inflammation, and
preserves glucose homeostasis despite HF diet challenge. Many of these
protective effects are driven by enhanced brown adipose tissue-dependent
energy expenditure and increased lipid mobilization from white adipose tissue.
Subsequent studies also identified a unique role of the TSP1-CD47 axis in nonalcoholic fatty liver disease. Together, this interaction contributes to the poor
oxidative environment so commonly observed in fatty liver disease. Future
studies should examine whether targeting CD47 with a functional blocking
antibody in vivo protects against cellular metabolic dysfunction and enhances
energy expenditure despite HF diet challenge. Results from these studies
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support the clinical application of targeting CD47 in obesity and its associated
comorbidities.
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Figure 5.1 Tissue-specific regulatory functions of CD47 in adipose tissues,
skeletal muscle, and the liver
Under HF diet conditions, CD47 deficient mice exhibit several protective
phenotypes in different metabolic tissues. Together, these effects significantly
reduced obesity-associated complications in CD47 deficient mice.
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Figure 5.2 Comparison of TSP1 deficient and CD47 deficient mice
phenotypes after 16-week HF diet challenge
This Venn diagram compares and contrasts the unique phenotypes between the
two cohorts of mice when challenged with HF diet (100, 128, 144, 156). It should
be noted that studies conducted with TSP1 deficient mice used different HF diets
(45-60% kCal from fat) and diet challenges ranged from 16-20 weeks. With the
CD47 deficient mice, the diet was composed of 60% kCal from fat and was
administered for 16 weeks.
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